

TECHNICAL REPORT

Fifth external quality assessment scheme for *Listeria monocytogenes* typing

ECDC TECHNICAL REPORT

Fifth external quality assessment scheme for *Listeria monocytogenes* typing



This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Taina Niskanen (ECDC Food- and Waterborne Diseases and Zoonoses Programme) and produced by Susanne Schjørring, Gitte Sørensen, Kristoffer Kiil, Malgorzata Ligowska-Marzeta, and Eva Møller Nielsen of the Foodborne Infections Unit at Statens Serum Institut, Copenhagen, Denmark.

Suggested citation: European Centre for Disease Prevention and Control. Fifth external quality assessment scheme for *Listeria monocytogenes* typing. Stockholm: ECDC; 2018.

Stockholm, August 2018

ISBN 978-92-9498-263-6

DOI 10.2900/653723

Catalogue number TQ-04-18-737-EN-N

© European Centre for Disease Prevention and Control, 2018

Reproduction is authorised, provided the source is acknowledged

Contents

Abbreviations	1
Executive summary	2
1. Introduction	3
1.1 Background	3
1.2 Surveillance of listeriosis	3
1.3 Objectives	4
1.3.1 Serotyping	4
1.3.2 Molecular typing-based cluster analysis	4
2. Study design	5
2.1 Organisation	5
2.2 Selection of test isolates	5
2.3 Carriage of isolates	5
2.4 Testing	5
2.5 Data analysis	6
3. Results	7
3.1 Participation	7
3.3 Serotyping	7
3.3.1 Conventional serotyping	7
3.3.2 Molecular serotyping	8
3.4 Molecular typing-based cluster analysis	10
3.4.1 PFGE-derived data	10
3.4.2 WGS-derived data	12
4. Discussion	19
4.1 Serotyping	19
4.1.1 Conventional serotyping	19
4.1.2 Molecular serotyping	19
4.2 Molecular typing-based cluster analysis	19
4.2.1 PFGE-derived data	19
4.2.3 WGS-derived data	19
5. Conclusions	21
6. Recommendations	22
6.1 Laboratories	22
6.2 ECDC and FWD-Net	22
6.3 EQA provider	22
7. References	23

Figures

Figure 1. Participant scores for conventional serotyping of the 11 test isolates	7
Figure 2. Correct conventional serotyping of three repeated isolates through EQA-1 to 5	8
Figure 3. Participant scores for molecular serotyping of the 11 test isolates	9
Figure 4. Correct molecular serotyping of three repeated isolates through EQA-1 to 5	9
Figure 5. Average score of the 11 test isolates	10
Figure 6. Difference between reported total number of bands (A and B) and shared bands (C and D) for each isolate	11
Figure 7. Reported SNP distances or allelic differences for each test isolate to selected cluster representative isolate 14	15
Figure 8. Minimum spanning tree of core genome multi locus sequence typing participant FASTQ files	15
Figure 9. Participant allele difference from reference result (EQA-provider) for each test isolate	16
Figure 10. Calculated allele difference between participant and REF isolates compared with selected QC parameters	17

Tables

Table 1. Number and percentage of laboratories submitting results for each method	7
Table 2. Results of cluster identification based on PFGE-derived data	11
Table 3. Results of cluster identification based on WGS-derived data	12
Table 4. Results of SNP-based cluster analysis	13
Table 5. Results of allele-based cluster analysis	13
Table 6. Summary of quantitative and qualitative parameters reported by participants	16
Table 7. Results of raw reads submitted by participants evaluated by EQA provider QC pipeline summarised by laboratory	18

Annexes

Annex 1. List of participants.....	24
Annex 2. Serotyping result scores.....	25
Annex 3. EQA provider cluster analysis based on PFGE-derived data.....	26
Annex 4. EQA provider cluster analysis based on WGS-derived data	27
Annex 5. Reported cluster of closely related isolates based on PFGE-derived data.....	28
Annex 6. Reported band differences	29
Annex 7. Reported sequencing details.....	30
Annex 8. Reported cluster of closely related isolates based on WGS-derived data	31
Annex 9. Reported SNP distance and allelic differences	32
Annex 10. Reported QC parameters.....	33
Annex 11. Calculated qualitative/quantitative parameters	34
Annex 12. EQA-5 laboratory questionnaire	39

Abbreviations

BN	BioNumerics
cgMLST	Core genome multilocus sequence type
wgMLST	Whole genome multilocus sequence type
EFSA	European Food Safety Authority
EQA	External quality assessment
EU/EEA	European Union/European Economic Area
EURL	European Union Reference Laboratory
FWD	Food- and waterborne diseases and zoonoses
FWD-Net	Food- and Waterborne Diseases and Zoonoses Network
PFGE	Pulsed-field gel electrophoresis
QC	Qualitative control
SNP	Single nucleotide polymorphism
SSI	Statens Serum Institut
ST	Sequence type
TESSy	The European Surveillance System
WGS	Whole genome sequence

Executive summary

This report presents the results of the fifth round of the external quality assessment (EQA-5) scheme for typing of *Listeria monocytogenes* (*L. monocytogenes*) organised for laboratories providing data to the Food- and Waterborne Diseases and Zoonoses Network (FWD-Net) managed by ECDC. Since 2012, the Section for Foodborne Infections at the Statens Serum Institut (SSI) in Denmark has arranged this EQA under a framework contract with ECDC. The EQA-5 contain serotyping and molecular typing-based cluster analysis.

Human listeriosis is a relatively rare but serious zoonotic disease with an EU notification rate of 0.47 cases per 100 000 population in 2016 [3]. The number of human listeriosis cases in the EU has increased since 2008, with the highest annual number of deaths since 2009 reported in 2015 at 270.

Since 2007, ECDC's FWD Programme has been responsible for the EU-wide surveillance of listeriosis, including facilitating detecting and investigating foodborne outbreaks. Surveillance data, including basic typing parameters for the isolated pathogen, are reported by Member States to The European Surveillance System (TESSy), including molecular typing data. This molecular surveillance system relies on the capacity of laboratories providing data to FWD-Net to produce comparable typing results. In order to ensure the EQA is linked to the development of surveillance methods used by public health national reference laboratories in Europe, EQA-5 contains a molecular typing-based cluster analysis using either pulsed-field gel electrophoresis (PFGE) and/or whole genome sequencing (WGS)-derived data, while quality assessment of PFGE performed in previous years has been excluded.

The objectives of the EQA are to assess the quality and comparability of the typing data reported by public health national reference laboratories participating in FWD-Net. Test isolates for the EQA were selected to cover isolates currently relevant to public health in Europe and represent a broad range of clinically relevant types for invasive listeriosis. Two separate sets of 11 test isolates were selected for serotyping and molecular typing-based cluster analysis. Twenty-two laboratories signed up and 20 completed the exercise, representing a decrease in participation of 13% from the previous assessment (EQA-4). This decrease in the number of participants may have been caused by adding WGS or removing PFGE as an independent part. The majority (65%) of participants completed the full EQA scheme. In total, 18 (90%) participants participated in the serotyping part and 15 (75%) in the molecular typing-based cluster analysis.

Conventional serotyping results were provided by six participants (30%) and molecular serotyping results were provided by 17 (85%) participants. Five participants performed both serotyping methods. The performance of molecular serotyping was highest, with 67% and 88% of the respective participants correctly serotyping all test isolates by conventional and molecular methods. The number of errors in the conventional serotyping was the same as in EQA-4. However, the number of participants decreased from nine to six. The performance of molecular serotyping increased from EQA-4, where 81% of the participants correctly serotyped all 11 test isolates. Since the first EQA in 2012, a trend towards substituting conventional serotyping with molecular serotyping has been observed. In EQA-5, only one participant exclusively performed conventional serotyping, while the remaining participants performed either both methods or only molecular serotyping.

Out of the 20 laboratories participating in EQA-5, 15 (75%) performed molecular typing-based cluster analysis using any method. The idea of the cluster analysis part of the EQA was to assess the public health national reference laboratories' ability to identify a cluster of genetically closely related isolates given that a multitude of different laboratory methods and analytical methods are used as the primary cluster detection approach in Member States. This part of the EQA was atypical in the sense that the aim was to assess the participants' ability to reach the correct conclusion, i.e. to correctly categorise the cluster test isolates, not to follow a specific procedure.

The cluster of closely related isolates contained four ST6 isolates that could be identified by both PFGE- (combination of *ApaI* and *Ascl* profiles) and WGS-derived data. The expected cluster was based on a pre-defined categorisation by the organiser. Seven laboratories used PFGE for cluster analysis and four of them also reported cluster analysis based on WGS data. Only one laboratory did not identify the correct cluster using PFGE.

Twelve laboratories performed cluster analysis using WGS-derived data. Performance was high, with 11 (92%) of the participants correctly identifying the cluster of closely related isolates. However, only two laboratories identified a cluster of three isolates due to data quality not meeting the laboratory's own QC standards for one of the cluster isolates. An allele-based method was preferred since 67% (8/12) used core genome multilocus sequence type (cgMLST) compared with 33% (4/12) using single nucleotide polymorphism (SNP) as the main reported cluster analysis. In this EQA, the participants were free to choose their preferred analytical method for the WGS-based cluster identification. In general, the reported cgMLST results were at a comparable level despite analysis with different schemes. The reported SNP results showed more variability. EQA results indicate that cgMLST is a good method for inter-laboratory comparability and cluster definition and cgMLST is more robust compared with non-standardised SNP based analysis.

1. Introduction

1.1 Background

ECDC is an independent EU agency with a mandate to operate dedicated surveillance networks. The mission of ECDC is to identify, assess and communicate current and emerging threats to human health from communicable diseases. The ECDC shall foster the development of sufficient capacity within the European Community's network for diagnosis, detection, identification and characterisation of infectious agents that may threaten public health. The ECDC shall maintain and extend such cooperation and support the implementation of quality assurance schemes [1].

External quality assessment (EQA) is an essential part of quality management and uses an external evaluator to assess the performance of participating laboratories on test samples supplied specifically for the purpose.

ECDC's disease-specific networks organise a series of EQAs for EU/European Economic Area (EEA) countries. The aim of the EQA is to identify needs of improvement in the laboratory diagnostic capacities relevant to epidemiological surveillance of communicable diseases as in Decision No 1082/2013/EU [2] and to ensure reliability and comparability of the results generated by the laboratories across all EU/EEA countries.

The main purposes of EQA schemes are to:

- assess the general standard of performance ('state of the art')
- assess the effects of analytical procedures (method principle, instruments, reagents, calibration)
- evaluate individual laboratory performance
- identify and justify of problem areas
- provide continuing education; and
- identify needs for training activities.

Since 2012, the section for Foodborne Infections at Statens Serum Institut (SSI), Denmark has been the EQA provider for the three lots covering typing of *Salmonella enterica* ssp. *enterica*, Shiga toxin/verocytotoxin-producing *Escherichia coli* (*E. coli*) (STEC/VTEC) and *L. monocytogenes*. In 2016, SSI was also granted the new round of tenders (2017-2020) for all three lots. For lot 3 (*L. monocytogenes*) from 2017, the EQA scheme no longer covers assessment of the PFGE quality. However, it still covers serotyping and includes a new part for cluster identification of *L. monocytogenes*. The present report presents the results of the fifth EQA scheme (*Listeria* EQA-5).

1.2 Surveillance of listeriosis

Human listeriosis is a relatively rare but serious foodborne disease, with high rates of morbidity, hospitalisation and mortality in vulnerable populations. The number of human listeriosis cases in the EU has increased since 2008 to 270 in 2015, the highest annual number of deaths reported since 2009. In the EU, 2,536 confirmed human cases of listeriosis were reported in 2016, corresponding to a notification rate of 0.47 cases per 100,000 population, which is similar to 2014 [3].

ECDC's FWD Programme is responsible for EU-wide surveillance of listeriosis and facilitating detecting and investigating foodborne outbreaks since 2007. One of the key objectives for the FWD programme is to improve and harmonise the surveillance system in the EU to increase scientific knowledge of aetiology, risk factors and burden of food- and waterborne diseases and zoonoses. Surveillance data, including some basic typing parameters for the isolated pathogen, are reported by Member States to TESSy. In addition to the basic characterisation of the pathogens isolated from infections, there is a public health value to use more discriminatory typing techniques in the surveillance of foodborne infections. Since 2012, ECDC has enhanced surveillance incorporating molecular typing data ('molecular surveillance'). Three selected FWD pathogens were included: *Salmonella enterica* ssp. *enterica*, *L. monocytogenes* and STEC/VTEC. The overall aims of integrating molecular typing into EU level surveillance are to:

- foster rapid detection of dispersed international clusters/outbreaks
- facilitate the detection and investigation of transmission chains and relatedness of isolates across MS and contribution to global investigations
- detect emergence of new evolving pathogenic isolates
- support investigations to trace-back the source of an outbreak and identify new risk factors; and
- aid the study of a particular pathogen's characteristics and behaviour in a community of hosts.

Molecular typing surveillance gives Member State users access to EU-wide molecular typing data for the pathogens included. It also gives users the opportunity to perform cluster searches and cross-sector comparability of EU-level data to determine whether isolates characterised by molecular typing at the national level are part of a multinational cluster that may require cross-border response collaboration.

The EQA schemes have targeted public health national reference laboratories already expected to be performing molecular surveillance at the national level.

1.3 Objectives

1.3.1 Serotyping

The EQA-5 scheme assessed the serotype determination by either conventional antigen-based typing of somatic 'O' antigens and flagellar 'H' antigens and/or PCR-based molecular serotyping.

1.3.2 Molecular typing-based cluster analysis

The objective of the *L. monocytogenes* EQA-5 was to assess the ability to detect a cluster of closely related isolates. Laboratories could perform analysis by using PFGE and/or derived data from WGS.

2. Study design

2.1 Organisation

Listeria EQA-5 was funded by ECDC and arranged by SSI following ISO/IEC 17043:2010 [4]. EQA-5 included serotyping and molecular typing-based cluster analysis and was carried out between September and December 2017.

Invitations were emailed to ECDC contact points in FWD-Net (30 countries) by 14 June 2017 with a deadline to respond by 28 June 2017. In addition, invitations were sent to EU candidate and potential candidate countries Albania, Montenegro, the former Yugoslav Republic of Macedonia, Serbia, Turkey, Bosnia and Herzegovina and Kosovoⁱ.

Twenty-two public health national reference laboratories in EU/EEA and EU candidate countries accepted the invitation to participate, but only 20 submitted results (Annex 1). The EQA test isolates were sent to participants on 30 August 2017. Participants were asked to submit their results by 9 October 2017 using the online form (Annex 12). If WGS was performed, submission of the raw reads (FASTQ files) to <https://sikkerftp.ssi.dk> was also requested.

The EQA submission protocol was distributed by e-mail and available at the online site.

2.2 Selection of test isolates

Twenty-two *L. monocytogenes* test isolates were selected to fulfil the following criteria:

- cover a broad range of the common clinically relevant types for invasive listeriosis
- include closely related isolates
- remain stable during the preliminary test period at the organising laboratory.

Thirty-two candidate isolates were analysed by the methods used in the EQA before and after re-culturing 10 times. All candidate isolates remained stable using these methods and the final selection of 22 test isolates, including technical duplicates (same isolate culture twice), was made. The 11 test isolates for serotyping were selected to cover different serotypes relevant for the current epidemiological situation in Europe. Isolates within serotypes 1/2a, 1/2b, 1/2c, 3a and 4b were selected. Among the serotyping test isolates, the three repeat isolates from EQA-1 to 4 were included to evaluate the performance development of the participants. Two sets of technical duplicates were also included this year. (Annex 2). The 11 test isolates for cluster analysis were selected to include isolates with different or varying relatedness isolates and different multi locus sequence types (ST 1, 6, 213, 382). Using either PFGE or WGS-derived data, the cluster of closely related isolates consisted of four *L. monocytogenes* ST6 isolates (one technical duplicate). The characteristics of all the *L. monocytogenes* test isolates are listed as Original/REF in Annexes 2–9.

2.3 Carriage of isolates

At the end of August 2017, all test isolates were blinded and shipped on 30 August. The protocol for the EQA exercise and a letter stating the unique isolate IDs were included in the packages, and distributed individually to the participants by e-mail on 29 August 2017 as an extra precaution. Nineteen participants received their dispatched isolates within one day, two within three days and one participant received the isolates six days after shipment. The parcels were shipped from SSI labelled as UN 3373 Biological Substance. No participants reported damage to the shipment or errors in the unique isolates IDs.

On 13 September 2017, instructions to the submission of results procedure were e-mailed to the participants. This included the links to the online uploading site and online submission form.

2.4 Testing

In the serotyping part, the 11 *L. monocytogenes* isolates were tested to assess the participants' ability to obtain the correct serotype. The participants could choose to perform conventional serological methods and/or PCR-based molecular serotyping (multiplex PCR according to the protocol suggested by Doumith *et al.* [5]). The serotypes were submitted in the online form.

ⁱ This designation is without prejudice to positions on status, and in line with UNSCR 1244/99 and the ICJ Opinion on the Kosovo Declaration of Independence.

In the cluster analysis part, the participants could choose to perform the laboratory part using PFGE (combining *Apal* and *Ascl* profiles) or WGS-derived data. The participants were instructed to report the IDs of the isolates included in the cluster of closely related isolates by method. If PFGE analysis was conducted, the participant reported the total number of bands and number of shared bands with a selected cluster representative isolate for both *Apal* and *Ascl*.

Laboratories performing WGS could use their own analysis pipeline for cluster analysis, e.g. single nucleotide polymorphism analysis (SNP-based) or whole genome multilocus sequence typing (wgMLST) /cgMLST (allele-based), and was asked to submit the isolates identified as cluster of closely related isolates based on the analysis used. The laboratories could report results from up to three analyses (one main and one to two additional), but the detected cluster had to be based on results from the main analysis. The laboratories reported SNP distance or allelic differences between a selected cluster isolate and each test isolate and uploaded the raw reads (FASTQ files).

2.5 Data analysis

As participating laboratories submitted their results, serotyping and cluster analysis results, as well as the participants' uploaded raw reads, were imported to a dedicated *Listeria* EQA-5 BioNumerics (BN) database. The EQA provider reported to participants when errors in the submission process were identified, thereby obtaining analysable results. The EQA provider was in contact with five participants in order to ensure no misunderstandings in data were submitted in the online submission form. Only two participants changed their submissions.

Serotyping results were evaluated according to the percentage of correct results, generating a score from 0-100%. Molecular typing-based cluster analysis was evaluated according to correct or incorrect identification of the expected cluster of closely related isolates based on a pre-defined categorisation by the organiser. The EQA provider's PFGE results were based on combined *Apal* and *Ascl* profiles. Cluster analysis based on WGS-derived data was derived on allele-based (cgMLST [6] and SNP analysis (NASP, [7])). The correct number of closely related *L. monocytogenes* isolates (4) could be identified by both PFGE- and WGS-derived data. The cluster contained four ST6 isolates: REF1, REF4, REF9 and REF11 (REF4 and REF9 were technical duplicates). The EQA provider found at most five allele differences or three SNPs between any two isolates in the cluster. The rest of the cluster test isolates were an additional four ST6s, one ST1, one ST213 and one ST382.

Individual evaluation reports were distributed to participants in December 2017 and certificates of attendance in March 2018. If WGS data were used, the evaluation report included a quality assessment made by the EQA provider's in-house quality control pipeline (e.g. coverage, N50, sequence length and number of contigs). The evaluation report did not include an evaluation based on quality thresholds.

3. Results

3.1 Participation

Laboratories could participate either in the full EQA scheme or one part only (serotyping or molecular typing-based cluster analysis). Of the 22 participants who signed up, 20 completed and submitted their results. The majority of participants (65%; 13/20) completed the full EQA scheme. In total, 18 (90%) participants participated in serotyping and 15 (75%) in cluster analysis. Conventional serotyping results were provided by six participants (30%) and molecular serotyping was provided by 17 (85%). Five participants performed both serotyping methods. Most participants (80%, 12/15) reported cluster analysis using WGS-derived data, while three (20%) reported only using PFGE data. Four participants (27%) submitted cluster data based on both PFGE and WGS. (Table 1).

Table 1. Number and percentage of laboratories submitting results for each method

	Serotyping				Cluster analysis			
	Conventional only	Molecular only	Both	Total	PFGE-only	WGS-only	Both	Total
Number of participants	1	12	5	18	3	8	4	15
Percentage of participants	6%	67%	28%	90%*	20%	53%	27%	75%*

Thirteen of the 20 participants (65%) completed both parts (serotyping and cluster analysis) of the EQA.


* Percentage of total number of participating laboratories (20)

3.3 Serotyping

3.3.1 Conventional serotyping


Six participants performed conventional serotyping of *L. monocytogenes* (Figure 1). Performance was high, with four (67%) participants correctly serotyping all 11 test isolates. Two participants (100 and 56) reported the incorrect result of the 3a isolate as a 1/2a. Laboratory 56 also failed one of the two 1/2b isolates when reporting 1/2a.

Figure 1. Participant scores for conventional serotyping of the 11 test isolates



Arbitrary numbers represent participating laboratories. Bars represent the percentage of correctly assigned serotypes for the 11 test isolates (SERO1-11).


To follow the development of each laboratory's performance, three isolates of different serotypes were included in EQA-1 to 5: SERO6 (1/2a - IIa), SERO8 (4b - IVb) and SERO9 (technical duplet with isolates SERO3) (1/2c - IIc). Figure 2 shows the individual participants' performances on conventional serotyping of these three repeated isolates during the five EQAs. Conventional serotyping results on the repeated isolates shows stability and high performance among the participants. None of the participants failed to serotype all three isolates correctly in EQA-5.

Figure 2. Correct conventional serotyping of three repeated isolates through EQA-1 to 5

Arbitrary numbers represent the participating laboratories. Bars represent the number of correctly assigned serotypes for the three repeated isolates (SERO6, 8 and 9).


3.3.2 Molecular serotyping

Seventeen participants performed molecular serotyping of *L. monocytogenes* (Figure 3), including two new laboratories (96 and 130). Molecular serotyping was carried out in accordance to guidelines in Doumith *et al.* [5] and nomenclature from Doumith *et al.* [8] was used. Fifteen (88%) of the 17 participants were able to correctly serotype all 11 EQA test isolates. The two new laboratories and the new participants from EQA-4 were among the 15 participants. Only two isolates were incorrectly serotyped by one participant each. One of the errors was in isolate SERO9 that was a technical duplicate of isolate SERO3, which the same participant was able to serotype correctly.

Figure 3. Participant scores for molecular serotyping of the 11 test isolates

Arbitrary numbers represent the participating laboratories. Bars represent the percentage of correctly assigned serotypes for the 11 test isolates SERO1-11.

Figure 4 shows the individual participants' performances on molecular serotyping of the three repeated isolates during the five EQAs. As for conventional serotyping, the general performance among participating laboratories was high and stable. The majority of participants (70%) correctly serotyped all three repeated isolates when participating.


Figure 4. Correct molecular serotyping of three repeated isolates through EQA-1 to 5

Arbitrary numbers represents the participating laboratories. Bars represent the number of correctly assigned serotypes for the three repeated isolates (SERO6, 8 and 9).

Laboratory did not correctly identify any of the three repeated isolates.

Ten (91%) of the 11 test isolates were correctly serotyped by all participants in either the molecular or conventional serotyping part of the EQA (Figure 5). All participants in both parts of the serotype EQA correctly serotyped eight isolates, but errors were reported in isolates SERO2, SERO4 and SERO9. These isolates belonged to serotype 1/2b – IIb, 3a – IIa and 1/2c-IIc. Again this year, serotype 4b -IVb was the one serotype correctly assigned by all the participating laboratories, but isolates with 1/2a-IIa were also serotyped 100% correctly.

Figure 5. Average score of the 11 test isolates



Bars represent the percentage of correctly assigned serotypes by the participants.

3.4 Molecular typing-based cluster analysis

Participants were to correctly identify the cluster of closely related isolates defined by pre-categorisation from the EQA provider among the 11 cluster test isolates using either PFGE and/or WGS-derived data.

The EQA provider's PFGE results were based on combined *Apal* and *Ascl* profiles. The EQA provider's cluster analysis of WGS-derived data was based on an allele-based analysis (cgMLST [6]) and an SNP analysis (NASP [7]). The correct number of closely related isolates (4) could be identified by both PFGE and WGS-derived data. The cluster contained four ST6 isolates: REF1, REF4, REF9 and REF11 (REF4 and REF9 were technical duplicates). The EQA provider found at most five allele differences or three SNPs between any two isolates in the cluster. The rest of the cluster test isolates were an additional four ST6s, one ST1, one ST213 and one ST382 (Annexes 3–4).

3.4.1 PFGE-derived data

Seven (35%) participants performed cluster analysis using PFGE-derived data. Performance was high, with six (86%) of the participants correctly identifying the cluster of closely related isolates defined by a pre-categorisation from the EQA provider among the 11 cluster test isolates. Table 2 shows the overview of the isolate each participant included or excluded in their cluster identification. Laboratory 145 reported all 11 cluster isolates as part of the cluster of closely related isolates and had misunderstood the meaning of selecting a cluster representative. Instead, laboratory 145 selected *Salmonella* Braenderup (*S. Braenderup*) 9812, which is normally used as a size marker.

Table 2. Results of cluster identification based on PFGE-derived data

Isolate no.	ST	Laboratory ID						
		19	100	105	138	141	142	145
REF1 [†]	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REF2	1	No	No	No	No	No	No	Yes
REF3	6	No	No	No	No	No	No	Yes
REF4 ^{‡#}	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REF5	6	No	No	No	No	No	No	Yes
REF6	6	No	No	No	No	No	No	Yes
REF7	213	No	No	No	No	No	No	Yes
REF8	6	No	No	No	No	No	No	Yes
REF9 ^{‡#}	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REF10	382	No	No	No	No	No	No	Yes
REF11 [†]	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Cluster identified conclusion		Yes	Yes	Yes	Yes	Yes	Yes	No


[‡] Closely related isolates

[#] Technical duplicate isolates (Annex 5).

For each isolate, participants were instructed to report the total number of bands in the *ApaI* and *AscI* profiles separately. The number of bands shared between each test isolate and the selected cluster representative was reported for each enzyme (Figure 6). Data from the laboratory that had misunderstood this part is not shown in Figure 6 (Annexes 5–6).

In Figure 6, A and B show the difference between the number of bands reported by the participants and the number observed by the EQA provider for *ApaI* and *AscI* respectively. Only laboratory 138 reported one to two bands more or less in the *ApaI* profiles compared with the EQA provider's results.

C and D show the difference between the participants' reported number of shared bands with a selected cluster representative and the number observed by the EQA provider for *ApaI* and *AscI*, respectively. The majority of differences (12/14) were reported by laboratory 138, which recorded a higher number of shared bands using *ApaI* and a lower number of shared bands using *AscI*. Band differences above 2 were not observed.

Figure 6. Difference between reported total number of bands (A and B) and shared bands (C and D) for each isolate to selected isolates

Data from all eight ST6 isolates: REF1, REF3, REF4, REF5, REF6, REF8, REF9 and REF11.

C: Laboratory 141 only reported data for six isolates (Annex 6).

3.4.2 WGS-derived data

Reported results from participants

Twelve participants (60%) performed cluster analysis using WGS-derived data. Only one laboratory reported using external assistance for sequencing. Different sequencing platforms were listed among the participants: 1 MiniSeq, 6 MiSeq, 2 HiSeq, 1 NextSeq and 2 Ion Torrent. All reported using commercial kits for library preparation. Out of the 12 participants, eight (67%) used Illumina's Nextera kit. Two participants reported volume changes from the manufactory protocol and one laboratory- listed increased (5 ng) input DNA, altered PCR protocol to favour longer fragment sizes, adjustment of extension temperature from 72°C to 65°C and 'manual' normalisation using library concentration and fragment size as opposed to bead-based normalisation (Annex 7).

Performance was high in cluster analysis with WGS-derived data. Nine participants (75%) correctly identified the cluster of closely related isolates defined by pre-categorisation from the EQA provider among the 11 test isolates (Table 3). Laboratories 105 and 56 only analysed WGS data from 10 and seven isolates respectively due to data quality not meeting the laboratory's own QC standards, but identified the correct cluster among the remaining isolates. When these two laboratories are included, performance was even higher at 92% out of 11 laboratories. One laboratory included all ST6 isolates as being in the cluster of closely related isolates.

Table 3. Results of cluster identification based on WGS-derived data

Isolate no.	ST	Laboratory ID											
		19	35	56	70	105	108	129	135	141	142	144	146
REF1 [†]	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REF2	1	No	No	ND	No	No	No	No	No	No	No	No	No
REF3	6	No	No	No	No	No	No	No	No	No	No	No	Yes
REF4 [‡]	6	Yes	Yes	ND	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REF5	6	No	No	No	No	No	No	No	No	No	No	No	Yes
REF6	6	No	No	No	No	No	No	No	No	No	No	No	Yes
REF7	213	No	No	ND	No	No	No	No	No	No	No	No	No
REF8	6	No	No	ND	No	No	No	No	No	No	No	No	Yes
REF9 [‡]	6	Yes	Yes	Yes	Yes	ND	Yes	Yes	Yes	Yes	Yes	Yes	Yes
REF10	382	No	No	No	No	No	No	No	No	No	No	No	No
REF11 [†]	6	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Main analysis		Allele	Allele	SNP	Allele	SNP	SNP	Allele	Allele	Allele	Allele	Allele	SNP
Additional analysis		SNP				Allele					SNP		
Identified cluster		Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No

[†] Closely related isolates

[‡] Technical duplicate isolates

ST: Sequence type

ND: Not evaluated due to data quality not meeting laboratory's own QC thresholds

Allele: Allele-based analysis

SNP: Single-nucleotide polymorphism (Annex 8).

Laboratories were instructed to report the data analysis used for cluster identification and select a representative isolate in the cluster for reporting SNP distance or allelic differences between the selected isolate and each test isolate included in analysis. Laboratories could report results from up to three analyses (1 main and 1–2 additional), but the detected cluster had to be based on results from the main analysis.

Out of the six participants using SNP, only four (33%) used SNP as the main analysis for cluster detection, while two reported SNP as an additional analysis. Five out of six (83%) used a reference-based approach with different ST6 isolates as reference. Two used Burrows-Wheeler Aligner (BWA) and two used CLC as the read mapper, but different variant callers were used (Tables 4–5).

Table 4. Results of SNP-based cluster analysis

Lab ID	SNP-based						
	Approach	Reference	Read mapper	Variant caller	Assembler	Distance within cluster	Distance outside cluster
Provider	Reference-based	ST6 (REF4)	BWA	GATK		0-3	38-71
19*	Reference-based	ST6 ID 2362	BWA	GATK	SPAdes	0-4	43-81
56	Assembly-based			ksnp3		0-57#	561-591 (6109)
105	Reference-based	ST6 J1817	Bowtie2	VARSCAN 2		0-2#	22-42 (1049)
108	Reference-based	In-house strain resp ST	CLC assembly cell v4.4.2	CLC assembly cell v4.4.2		0-2	37-72
142*	Reference-based	<i>Listeria</i> EGDe (cc9)	CLC Bio	CLC Bio		0-1219	1223-2814 (8138)
146	Reference-based	ST6 ref. CP006046 ST1 ref. F2365 ST213/ST382 no ref.	BWA	In-house		0-358	

* Additional analysis

Only three isolates included due to data quality not meeting laboratory's own QC thresholds

✕ Reported distance to ST6 (non-ST6) isolates (Annex 9).

Eight of the nine participants that used allele-based analysis selected this method as the main analysis for cluster detection (Table 5 legend). Eight of nine (89%) used an assembly-based allele calling method and laboratory 19 used both mapping and assembly-based allele calling (Table 5). All reported using cgMLST, six (60%) used cgMLST Ruppitsch [9], two cgMLST Pasteur [6] and one an in-house cgMLST scheme.

Table 5. Results of allele-based cluster analysis

Lab ID	Allele based analysis					
	Approach	Allelic calling method	Assembler	Scheme	Difference within cluster	Difference outside cluster
EQA provider	BioNumerics	Assembly- and mapping-based	SPAdes	Applied Math (cgMLST/Pasteur)	0-3	24-1112
19	BioNumerics	Assembly- and mapping-based	SPAdes	Applied Math (cgMLST/Pasteur)	0-3	25-1120
35	SeqPher	Assembly-based only	Velvet	Ruppitsch (cgMLST)	0-2	16-1065
70	SeqPher	Assembly-based only	Velvet	Ruppitsch (cgMLST)	0-2	16-1062
105*	SeqPher	Assembly-based only	SPAdes v 3.80	Ruppitsch (cgMLST)	0-1#	23-812
129	SeqPher	Assembly-based only	Velvet	In-house (cgMLST)	0-4	15-862
135	SeqPher	Assembly-based only	CLC Genomics Workbench 10	Ruppitsch (cgMLST)	0-2	16-2042
141	SeqPher	Assembly-based only	SPAdes 3.9.0	Ruppitsch (cgMLST)	0-7	19-1060
142	Inhouse	Assembly-based only	SPAdes	Pasteur (cgMLST)	0	13-1120
144	SeqPher	Assembly-based only	Velvet	Ruppitsch (cgMLST)	0-2	16-1065


* Additional analysis

Only three isolates included due to data quality not meeting laboratory's own QC thresholds (Annex 9).

All nine laboratories performing cgMLST identified the correct cluster of closely related isolates (Figure 7). Eight laboratories reported allele differences of 0-4 within the cluster and laboratory 141 reported an allele difference within the cluster of at most 7 (Figure 7, Table 5). The differences reported depended on the isolate selected as cluster representative. Five laboratories selected REF11, four used REF4 or REF9 (technical duplicates) and none selected REF1 (Figure 7).

Four other test isolates (REF3, REF5, REF6 and REF8) were also ST6, but not pre-defined by the EQA provider as part of the cluster. Based on cgMLST, the nine laboratories reported allele differences to the selected cluster isolate at 13-50 for this group of isolates. Three test isolates (REF2, REF7 and REF10) were not ST6 and allele differences to the selected cluster isolate at 839-2042 were reported (Table 5, Annex 9).

Laboratories 19 and 142 used the same cgMLST scheme as the EQA provider (cgMLST/Pasteur) [6] and all but one laboratory used the Ruppitsch scheme [9]. All participants reported similar results, with allele differences within the cluster of 7 at most.

Figure 7. Reported SNP distances or allelic differences for each test isolate to selected cluster representative isolate

* Additional analysis

SNP: Single nucleotide polymorphism

Selected cluster representative marked as REF in dark green: Reported cluster of closely related isolates

Light green: Not reported as part of cluster.


Of the six laboratories performing SNP analysis (four as main analysis and two as additional), laboratories 19, 56, 105 and 108 identified the correct cluster of closely related isolates (Figure 7). Laboratory 146 performed only SNP analysis and could not identify the correct cluster. Laboratory 142 correctly identified the cluster using main analysis, but the additional SNP analysis provided no clear separation of cluster and non-cluster isolates.

The reported SNP differences within the cluster varied from 0-4 (laboratories 19, 105 and 108) to 0-57 (laboratory 56). If the cut-off for cluster definition used by laboratory 56 was used on data from laboratory 19, 105 and 108, all eight ST6 isolates would have been included in the cluster. Very high SNP differences within the cluster were also reported by laboratories 146 (0-309) and 142 (0-1219). Laboratory 146 identified a cluster of eight isolates as closely related based on a reported SNP difference of 0-358 to the selected cluster representative isolate. In addition, the same laboratory selected a non-cluster isolate (REF3) as the cluster representative, while the other five laboratories performing SNP analysis selected REF11 (two), REF1 (one), or REF4 or 9 (two) as the cluster representative.

Analysis of raw reads uploaded by participants

In addition to the reported cluster identification, participants submitted their FASTQ files to be evaluated by the EQA provider. The FASTQ files were uploaded to an Applied Maths calculation engine for allele calling (Institut Pasteur)[6] and evaluated by the EQA provider's in-house quality control (QC) pipeline [10].


The overall cgMLST analysis, shown in the minimum spanning tree (MST) based on submitted raw reads (FASTQ files) from 12 laboratories reveals clear clustering of the results for each test isolate (Figure 8). One laboratory seem to have switched the labels of the isolates and the numbering. All nine results in Figure 8 where an isolate (colour) is clustered wrongly are due to data from laboratory 146. It appears to be a labelling switch and not sequencing errors as the isolates still cluster as expected.

Figure 8. Minimum spanning tree of core genome multi locus sequence typing participant FASTQ files

Minimum spanning tree (MST) in log scale of core genome multi-locus sequence typing (cgMLST)[6] based on submitted raw reads (FASTQ files). Each of the REF1–11 test isolates have a different colour. REF results from the EQA-provider are in grey. Of the 12 laboratories, two submitted only 10 and 7 FASTQ files respectively due to data quality not meeting the laboratory's own QC thresholds.

The allele differences in Figure 8 do not exactly match those illustrated in the individual reports and consequently those in Figures 9–10, where the same data are used. This discrepancy is caused by loci being dropped if they do not pass QC in all isolates in the analysis. Joint analysis thus contains fewer loci.

Each laboratory performed cgMLST on the submitted raw reads (FASTQ files), applying Applied Maths allele calling with the Pasteur scheme [6]. For each laboratory, the minimum spanning tree (MST) was calculated for the submitted data along with the EQA providers reference isolates. Figure 9 shows the allele differences between each submitted sequence and the corresponding reference. Data from laboratory 146 are omitted from the figure since the switched isolate labels make the allele differences nonsensical. An estimate of the performance of laboratory 146 correcting for the mixed labels shows concordance with the reference except for two isolates with one allele difference each.

Figure 9. Participant allele difference from reference result (EQA-provider) for each test isolate

Allele difference of participant isolates from corresponding REF isolates (EQA provider) based on submitted raw reads (FASTQ files). Data from laboratory 146 are excluded due to switched isolate labels. Only 7 and 10 isolates respectively are used for laboratories 56 and 105 due to data quality not meeting laboratory's own QC thresholds.

For 74 of 116 results (64%), no difference was identified. For 40 results (34%), a difference of 1–2 alleles from the REF isolate was calculated and a difference of 3 and 6 alleles were seen from laboratories 141 and 129 for only 2 results (2%). Data from five of the 11 laboratories (70, 108, 129, 141 and 144) covered 76% (32/42) of all allele differences. Laboratories 70 and 144 had 8 and 9 isolates respectively, with one or more allele differences. The provider result for REF11 was one allele removed from the majority of the participants and the two results with more than two allele differences both originated from REF1 (data not shown).


Separately, the laboratories listed quantitative and qualitative QC parameters used to evaluate their data. As seen in Table 6, coverage was the most widely used QC parameter, with acceptance thresholds ranging from 20–60X coverage. CgMLST quality metrics were widely used, as was the correct assembly length and a genus/species confirmation or contamination check. For the full QC evaluation of all isolates, see Annex 10.

Table 6. Summary of quantitative and qualitative parameters reported by participants

Parameters	Number of laboratories
Coverage	10
Number of good cgMLST targets	7
Genome size	6
Confirmation of genus	6
Q score (Phred)	5
Number of contigs	3
FastQC per base sequence content	2
N50	2
Others	5

Figure 10A shows the allele differences from Figure 9 plotted against the coverage of the individual isolate. The isolate that differs by 6 alleles has a coverage that exceeds the reported QC coverage thresholds. Figure 10B shows the allele differences from Figure 9 plotted against the number of contigs with coverage below 25. Both the isolates with 3 and 6 allele differences have a higher number of low-coverage contigs.

Figure 10. Calculated allele difference between participant and REF isolates compared with selected QC parameters



Allele difference of participant isolates from corresponding REF isolates from Figure 9 plotted against average coverage of submitted raw reads (FASTQ files) calculated by EQA provider QC pipeline (A) and number of contigs with minimum coverage <25 when reads are mapped back against SPAdes de novo assembly (B).

For each laboratory, the submitted raw reads (FASTQ files) were evaluated by the EQA provider's in-house quality control pipeline [10]. Table 7 shows the QC parameters and range of QC values per laboratory. For the full QC evaluation of all isolates, see Annex 11.

According to the QC parameters, sequencing quality was uniformly good. A single isolate was contaminated. One laboratory withheld the results from four isolates due to data quality not meeting the laboratory's own QC thresholds. Coverage was high overall. Some laboratories had high variation between isolates of up to 5X. Laboratories 142 and 105, when excluding the contaminated isolate, had very good control of the concentration normalisation step as seen from the low coverage variation.

Table 7. Results of raw reads submitted by participants evaluated by EQA provider QC pipeline summarised by laboratory

Parameters	Ranges*	Laboratory ID											
		19	35	56	70	105	108	129	135	141	142	144	146
No. of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1	1
Detected species	{Lm}	Lm	Lm	Lm	Lm	Lm-N	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		1.5-2.5	0.6-2.5	0.6-2.2	1.5-2.9	0.7-50.8	1.1-1.8	0.6-1.7	0.5-1.0	0.9-1.8	0.8-1.4	0.2-1.3	0.4-2.0
Length at 25 x min. coverage (Mbp)	{>2.8 ∧ <3.1}	2.9-3.0	2.9-3.0	1.8-2.7	2.9-3.0	0.1-3.0	2.9-3.0	2.9-2.9	2.9-3.0	1.0-3.0	2.9-3.0	2.9-3.0	2.9-3.0
Length [0-25] x min. coverage (Mbp)	{<0.25}	0	0	0	0	0-0.9	0	0-0.1	0	0.0-1.8	0	0	0
No. of contigs at 25 x min. coverage	{>0}	14-21	12-25	876-1056	17-45	14-193	57-146	15-47	17-24	19-85	13-17	11-17	17-25
No. of contigs [0-25] x min. coverage#	{<1000}	0	0	0	0-4	0-517	0-5	0-24	0	0-165	0-2	0	0-1
Average coverage	{>50}	160-224	40-175	61--104	51-100	8-94	30-70	50-244	153-221	24-126	40-58	75-128	140-200
No. of reads (x 1000)		1741-2457	250-1120	707-1278	528-1035	345-622	285-689	530-2704	1898-2835	158-883	261-385	525-881	2148-3169
No. of trimmed reads (x1000)		1721-2428	248-1110	691-1235	524-1028	342-609	521-617	523-2677	1878-2800	150-865	295-380	534-870	2148-3169
Maximum read length		151	301	285-365	151	301	241-319	151	126	301	251	251	101
Mean read length		140-142	215-251	217-229	143-146	204-241	186-200	139-145	123-124	218-235	245-234	210-227	97-100
Read insert size		267.9-305	333-394	NA	288-391	199-363	NA	244-450	326-351	279-358	361-399	280-327	204-360
Insert size StdDev		100-106	158-199	NA	100-149	67-158	NA	108-196	175-188	102-130	157-174	93-125	85-169
N50 (kbp)		238-551	274.4-558	1.4-3.4	162.3-318	1.3-407	34.0-87	125-551	295-482	22-263	262-556	353-558	286-510
N75 (kbp)		143.3-257.3	139-263	0.9-1.9	78-238	0.8-262	23-45	61-258	142-258	11-236	198-262	183-263	144-262

* Indicative QC range

Lm: *L. monocytogenes*

N: *Neisseria*

Number of contigs with coverage < 25 (Figure 10B)

4. Discussion

4.1 Serotyping

Eighteen laboratories participated in the serotyping part of the EQA-5, of which six participants (33%) provided conventional serotyping results and 17 (94%) provided molecular serotyping results. Five participants performed both serotyping methods. Performance was high for both methods, with 67% and 88% of the participating laboratories correctly serotyping all 11 *L. monocytogenes* test isolates by conventional or molecular methods respectively.

4.1.1 Conventional serotyping

The performance of the conventional serotyping results was acceptable (67%), but a decrease was observed compared with EQA-4, where the same number of errors were reported, but more laboratories participated. Again this year, the main problem was an uncommon serotype 3a isolate that two laboratories reported as 1/2a. One of the laboratories repeated the mistake from EQA-3, reporting 1/2a instead of 3a. One explanation for this mistyping could be difficulties in agglutination with the IV serum that defines the O:3 groups. If the I/II polyvalent sera are positive and the I monovalent serum is negative, the agglutinations need to be evaluated in parallel when observing negative results for I and IV monovalent sera. This step requires well trained eyes in order to see the agglutination in IV monovalent serum and not the I serum. Comparing the conventional serotyping results from EQA-1 to -5, the three repeated isolates showed stable high performances among participants during the EQAs and all six participants serotyped the three repeated isolates correctly. All participants performed at the same level or better than the year before.

4.1.2 Molecular serotyping

The performance of the PCR-based molecular serotyping was high, with 88% of participants obtaining a score of 100% correct. The two errors were from two different laboratories reported in two different isolates. One of the errors was in isolate SERO9, a technical duplicate of SERO3, which the participant correctly serotyped as IIc. The general performance among the participating laboratories was high and increased from EQA-1 (57%, 7 participants) to -5 (88%, 17 participants). The majority of participants (94%) correctly serotyped all three repeated isolates. All but one participant performed at the same level or better than the year before.

4.2 Molecular typing-based cluster analysis

The EQA scheme no longer covers PFGE as an independent part, but by adding cluster identification using either PFGE and/or WGS-derived data, this EQA is contemporary with the development of surveillance methods used by public health national reference laboratories in Europe. This adjustment of the EQA appears to be well accepted by the Member States as 15 of the twenty laboratories (75%) participated. Only seven participated in cluster identification using PFGE-derived data and only three of them did not also participate in cluster identification using WGS-derived data. However, six laboratories participating in PFGE in EQA-4 did not participate in cluster identification in EQA-5. This decrease in the number of participants could be caused by adding WGS or removing PFGE as an independent part and no longer give the laboratories an external quality assessment of their PFGE performance.

4.2.1 PFGE-derived data

Out of the twenty laboratories, seven (35%) performed cluster analysis using PFGE-derived data. Performance was high, with 6 participants (86%) correctly identifying the cluster of closely related isolates. The present cluster designed by the EQA provider allowed the participants to detect the same number of closely related isolates by both PFGE and WGS, but both *Apal* and *Ascl* enzymes were needed to identify the correct number of isolates by PFGE. Neither the *Apal* nor *Ascl* profiles alone would have delineated the cluster correctly. Only one laboratory did not identify the cluster. However, this was probably due to not understanding the terms 'reference' used for *S. Braenderup* and 'a cluster representative isolate'. Another laboratory that had minor differences in the total number of observed bands in *Apal* profiles and in shared bands in both *Apal* and *Ascl* profiles compared with the EQA provider did identify the correct cluster.

4.2.3 WGS-derived data

Twelve out of the twenty laboratories (60%) performed cluster analysis using WGS-derived data. Performance was very high, with 11 (92%) correctly identifying the cluster of closely related isolates, but two laboratories could not obtain WGS data for all test isolates. Only one laboratory reported the use of external assistance for sequencing and the majority (10/12) reported using an Illumina platform. All reported using commercial kits for preparing the library.

Out of the twelve laboratories, eight (67%) reported using an allele-based method as the main analysis and four (33%) reported using SNP analysis. The one laboratory not identifying the correct cluster had used SNP analysis. If only evaluating the main analysis of the laboratories reporting the correct cluster, the distances reported using SNP-based analysis showed a higher variation within the cluster isolates (0-57) than the allele differences reported using cgMLST (0-7).

Of the laboratories reporting SNP distances, three laboratories (50%) reported distances comparable to those reported using allele-based methods. The remaining three reported SNP distances that were several orders of magnitude higher. One laboratory used cgMLST as the main analysis and SNP analysis as an additional analysis. In the SNP analysis, it identified a very large number of SNPs and could not separate the cluster from the non-cluster isolates using the submitted SNP distances. Another laboratory correctly identified the cluster, but with a level of variance within the cluster incomparable to that found by the remaining laboratories. If a cluster was defined as any isolate within 57 SNPs of the selected reference isolate, other laboratories would report more than the correct four cluster isolates.

This is problematic in terms of inter-laboratory comparability and cluster definitions and makes the use of SNP distances obtained from non-standardised SNP analyses less suitable for communicating about genetic clusters when investigating international outbreaks. The reported high SNP distances seem unlikely to represent real biological divergence and are more likely to be artefacts of SNP calling.

Reported cgMLST results were much more comparable, with 0-7 allelic differences within the cluster isolates and 13-2042 outside the cluster, despite not being analysed using the same scheme. Analysing all participants' raw reads in the same scheme [6], the maximum distance between any two cluster isolates were 9 allele differences (data not shown), similar to the distances reported by the participants. The choice of assembly tool seems not to have influence on the number of allelic differences.

The reported QC parameters (quantitative and qualitative) were used by the participants as QC of their data before analysis and submission. The main reported QC parameters, coverage, cgMLST allele calls and species confirmation, are all essential for the end use of the data.

In order to compare the quality of the raw data, the EQA provider analysed the submitted raw reads to obtain selected QC parameters. There appear to be laboratory differences in accuracy. The sequencing depths of the submitted raw reads vastly exceeded QC coverage thresholds reported by the participants'. This in combination with a high variation in sequencing depth makes sequencing more costly than necessary. Decreasing the variation in sequencing depth and subsequently the necessary overall sequencing depth could allow for significant savings in terms of higher multiplexing on the sequencer.

The EQA provider's analysis of the submitted raw data showed that when using a standardised cgMLST analysis, a random variation of 1–2 alleles is likely to be observed even with high coverage (Figure 10). Only two isolates showed more variation, deviating from the EQA provider's reference with 3 and 6 alleles respectively (both isolates correspond to REF1). The result with 3 allele differences from the references had low overall sequencing depth. The result with 6 allele differences had fairly high overall coverage, but upon assembly, a number of low-coverage contigs occurred. Apparently this uneven coverage can lead to inflated allele differences. Low average coverage can be resolved by lower multiplexing of samples in sequencing runs and more care in the normalisation of the multiplexed samples. The cause of the uneven coverage is unknown.

5. Conclusions

Twenty laboratories participated in the EQA-5 scheme, with 18 (90%) performing serotyping and 15 (75%) cluster identification. In the EQA program, a change was made from including quality assessment of PFGE in EQA-4 to including a molecular typing-based cluster analysis using either PFGE and/or WGS-derived data in EQA-5. This adjustment of the EQA seemed to be well accepted by Member States, but a decrease in the number of participants was seen compared with previous years. The level of participation in serotyping remained the same, but not all laboratories performing PFGE (EQA-4) signed up for molecular typing-based cluster analysis.

In the present EQA, only a small percentage of the serotyping participating laboratories (6%, 1/18) solely performed conventional serotyping. Most laboratories (67%, 12/18) performed only molecular serotyping and 28% molecular serotyping in combination with the conventional serotyping. In general, a trend towards substituting conventional serotyping with molecular was observed through the five EQAs, reflecting a decrease in participation in conventional serotyping from 63% to 33% and an increase in molecular serotyping from 44% to 94% from EQA-1 to 5.

In general, the quality of serotyping was high. The performance of molecular serotyping was highest, with 67% and 88% of the participants correctly serotyping all test isolates by conventional and molecular methods respectively. In EQA-3, the main problem was an uncommon serotype 3a isolate, which again caused two out of the three errors in the conventional serotyping this year.

Incorporating molecular typing-based cluster analysis in this EQA is up to date with the development of surveillance methods used by public health national reference laboratories in Europe. Out of the twenty laboratories participating the EQA-5, fifteen (75%) performed cluster analysis using either PFGE and/or WGS-derived data.

Seven laboratories participated using PFGE for cluster analysis. Three participated solely using PFGE-derived data for analysis. Only one did not identify the correct cluster using PFGE, probably due to misunderstanding the purpose of the analysis. Correct identification of the isolates in the cluster of closely related isolates needed analysis with both enzymes (*Apal* and *Ascl*).

Twelve laboratories performed cluster analysis using WGS-derived data. The performance was high, 11 (92%) of the participants correctly identified the cluster of closely related isolates, but two laboratories only identified a cluster of three isolates due to data quality not meeting the laboratory's own QC thresholds for one of the cluster isolates.

An allele-based method was preferred, as 67% (8/12) used cgMLST compared to 33% (4/12) using SNP as the main reported cluster analysis. In general, the reported cgMLST results were at a comparable level of allelic difference (0-7) within the cluster isolates despite analysis with different schemes. This highlights the advantages of cgMLST as a method for inter-laboratory comparability and communication about cluster definitions. The EQA results also illustrated the challenges in using non-standardised SNP analysis as a method for inter-laboratory comparison and cluster definition.

The current EQA scheme for *L. monocytogenes* typing is the fifth organised for laboratories in FWD-Net. The molecular surveillance system implemented as part of TESSy relies on the capacity of FWD-Net laboratories to produce analysable and comparable typing results in a central database. In 2018, it is planned to allow WGS variables for *L. monocytogenes* to be submitted to TESSy to be used for EU-wide surveillance and cross-sector comparison.

6. Recommendations

6.1 Laboratories

Two participants in the WGS-based cluster analysis experienced generated sequences not meeting their own QC criteria and had neither the time nor resources to repeat the failed analyses. Participants are encouraged to assign sufficient resources to repeat failed analysis if required.

Results from the EQA disclose higher variations between different SNP pipelines analysing the same isolate compared with allele-based analysis. For some laboratories, a more conservative SNP calling would facilitate better cluster delineation. Generally, standardization of analysis parameters would improve inter-laboratory comparability.

One laboratory mislabelled the submitted raw read files. Laboratories are encouraged to check correct relabelling by checksum or otherwise before submission if internal labelling is used.

6.2 ECDC and FWD-Net

ECDC plans to encourage and assist new participants ever better, potentially with training or workshops. ECDC is working on standardise the TESSy system for use of MLST nomenclature and cgMLST.

6.3 EQA provider

This year, the EQA provider changed the invitation letter to contain the recommended methods and a short description of the molecular typing-based cluster analysis. The requirements for submission and evaluation criteria were also listed. The submission protocol was short and precise, but some laboratories did not follow protocol when labelling the FASTQ files. In the next round, participants who do not comply with the requested naming convention of FASTQ files will be asked to rename their files.

The link to the online submission was personal to the e-mail listed during registration, so participants need to circulate the e-mail within their institute. The participants will be made aware of this issue in the next round.

Participants were instructed to perform the PCR for the molecular serotyping. It is unclear if some of the participants have already replaced it with an *in silico* PCR (gene detected based on WGS). This will be possible to report in the next round of the EQA.

In the next round of EQAs, laboratories can submit the ST of the isolates in the cluster analysis. They will also be asked to report the number of loci in the used allelic scheme and the name of the used SNP-pipeline if publicly available. The EQA provider will try to give the participants more time to test and report the results.

7. References

1. Official Journal of the European Union. Regulation (EC) No 853/2004 of the European Parliament and of the Council of 21 April 2004 establishing a European Centre for Disease Prevention and Control, Article 5.3. Strasbourg: European Parliament and European Council; 2004. Available from: http://ecdc.europa.eu/en/aboutus/Key%20Documents/0404_KD_Regulation_establishing_ECDC.pdf.
2. Official Journal of the European Union. Decision No 1082/2013/EU of the European Parliament and the Council of 22 October 2013 on serious cross-border threats to health and repealing Decision No 2119/98/EC (Text with EEA relevance). Strasbourg: European Parliament and European Council; 2013. Available from: http://ec.europa.eu/health/preparedness_response/docs/decision_serious_crossborder_threats_22102013_en.pdf.
3. European Food Safety Authority and European Centre for Disease Prevention and Control. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2016. EFSA Journal 2017;15(12):5077.
4. International Organization for Standardization. ISO/IEC 17043:2010 Conformity assessment -- General requirements for proficiency testing [Internet]. Vernier: ISO; 2015 [cited 20 June 2018]. Available at: http://www.iso.org/iso/catalogue_detail.htm?csnumber=29366.
5. Doumith M, Buchrieser C, Glaser P, Jacquet C, Martin P. Differentiation of the Major *Listeria monocytogenes* serovars by multiplex PCR. J J Clin Microbiol. 2004 Aug;42(8):3819-3822.
6. Moura A, Criscuolo A, Pouseele H, Maury MM, Leclercq A, Tarr C, et al. Whole genome-based population biology and epidemiological surveillance of *Listeria monocytogenes*. Nat Microbiol. 2016 Oct 10;2:16185. Available from: <https://www.nature.com/articles/nmicrobiol2016185>.
7. Doumith M, Jacquet C, Gerner-Smidt P, Graves LM, Loncarevic S, Mathisen T, et al. Multicenter validation of a multiplex PCR assay for differentiating the major *Listeria monocytogenes* serovars 1/2a, 1/2b, 1/2c, and 4b: toward an international standard. J Food Prot. 2005 Dec;68(12):2648-50.
8. Sahl JW, Lemmer D, Travis J, Schupp JM, Gillece JD, Aziz M, et al. NASP: an accurate, rapid method for the identification of SNPs in WGS datasets that supports flexible input and output formats. Microb Genom. 2016 Aug 25;2(8):e000074. Available from: <http://mgen.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000074>.
9. Ruppitsch W, Pietzka A, Prior K, Bletz S, Fernandez HL, Allerberger F, et al. Defining and Evaluating a Core Genome Multilocus Sequence Typing Scheme for Whole-Genome Sequence-Based Typing of *Listeria monocytogenes*. J Clin Microbiol. 2015 Sep;53(9):2869-76.
10. Statens Serum Institut. SerumQC [Internet, software package]. Copenhagen: Statens Serum Institut; 2017. Available from: <https://github.com/ssi-dk/SerumQC>.

Annex 1. List of participants

Country	Laboratory	National institute
Austria	NRL Listeria Austria	AGES - Austrian Agency for Health and Food Safety
Belgium	National Reference Centre Listeria	Scientific Institute Public Health
Denmark	Foodborne Infections	Statens Serum Institut
Finland	Expert Microbiology	National Institute for Health and Welfare
France	NRC Listeria	Institut Pasteur
Germany	NRC Salmonella and Other Bacterial Enterics	Robert Koch- Institute, Branch Wernigerode
Greece	National Reference Laboratory for Salmonella and Other Enteropathogens	National School of Public Health
Hungary	Department of Phage-Typing and Molecular Epidemiology	National Public Health Institute
Ireland	National Salmonella, Shigella and <i>Listeria</i> Reference Laboratory	University Hospital Galway
Italy	Department of Food Safety, Nutrition and Veterinary Public Health	Istituto Superiore di Sanità
Latvia	National Microbiology Reference Laboratory	Riga East University Hospital
Lithuania	National Public Health Surveillance Laboratory	Nacionalinė Visuomenės Sveikatos Prižiūros Laboratorija
Luxembourg	Epidémiologie et Génomique Microbienne	Laboratoire National de Santé
Portugal	LNR de Infecções Gastrointestinais	Instituto Nacional de Saúde Doutor Ricardo Jorge
Slovakia	NRC for Listeriosis	Regional Public Health Authority
Slovenia	Department for Public Health Microbiology	National Laboratory of Health, Environment and Food, Centre for Medical Microbiology
Spain	<i>Neisseria</i> , <i>Listeria</i> and <i>Bordetella</i> Unit (National Centre for Microbiology)	Instituto de Salud Carlos III
Sweden	Microbiology	Folkhälsomyndigheten
The Netherlands	Centre for Infectious Research, Diagnostics and Screening	National Institute for Public Health and the Environment
UK	Gastrointestinal Bacteria Reference Unit	Public Health England

Annex 2. Serotyping result scores

Conventional serotyping

Isolate no.	Provider	Laboratory ID						Total score
		49	56	100	141	142	145	
SERO1	4b	4b	4b	4b	4b	4b	4b	100/1
SERO2	1/2b	1/2b	1/2a	1/2b	1/2b	1/2b	1/2b	83
SERO3 ^{#1}	1/2c	1/2c	1/2c	1/2c	1/2c	1/2c	1/2c	100/67
SERO4	3a	3a	1/2a	1/2a	3a	3a	3a	67
SERO5 ^{#2}	1/2b	1/2b	1/2b	1/2b	1/2b	1/2b	1/2b	100/100
SERO6	1/2a	1/2a	1/2a	1/2a	1/2a	1/2a	1/2a	100
SERO7	4b	4b	4b	4b	4b	4b	4b	100
SERO8	4b	4b	4b	4b	4b	4b	4b	100
SERO9 ^{#1}	1/2c	1/2c	1/2c	1/2c	1/2c	1/2c	1/2c	100
SERO 10	1/2a	1/2a	1/2a	1/2a	1/2a	1/2a	1/2a	100
SERO 11 ^{#2}	1/2b	1/2b	1/2b	1/2b	1/2b	1/2b	1/2b	100
Total score		100	82	91	100	100	100	

Molecular serotyping


		Laboratory ID																	
Isolate no.	Provider	19	35	56	70	88	96	100	105	108	129	130	141	142	143	144	145	146	Total score
SERO1	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	100
SERO2	IIb	IIb	IIb	IIa	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	94
SERO3 ^{#1}	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	100
SERO4	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	100
SERO5 ^{#2}	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	100
SERO6	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	100
SERO7	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	100
SERO8	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	IVb	100
SERO9 ^{#1}	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIc	IIa	IIc	IIc	IIc	IIc	IIc	IIc	IIc	94
SERO 10	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	IIa	100
SERO 11 ^{#2}	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	IIb	100
Total score		100	100	91	100	100	100	100	100	100	91	100	100	100	100	100	100	100	

Pink: Incorrect

Purple: Repeat isolates in EQA-1 to 5


Set of technical duplicates 1 and 2

Annex 3. EQA provider cluster analysis based on PFGE-derived data



Cluster of closely related isolates: REF1, REF4, REF9 and REF11

Annex 4. EQA provider cluster analysis based on WGS-derived data



Minimum spanning tree of core genome multi locus sequence typing (cgMLST, [6]) profiles of *L. monocytogenes* EQA-5 isolates. Logarithmic scaling in BioNumerics.

Dark grey: Cluster isolates

Light grey: Outside cluster isolates

Annex 5. Reported cluster of closely related isolates based on PFGE-derived data

Lab ID	Reported cluster	Corresponding REF isolates	Correct
Provider	REF1, REF4, REF9, REF11 (4 and 9 technical duplicates)		
19	3362# 2539 2691 2719	REF4, REF1, REF9, REF11	Yes
100	2080 2295 2405 2499	REF4, REF9, REF11, REF1	Yes
105	2073 2709 2805 2978	REF4, REF9, REF1, REF11	Yes
138	2141 2349 2778 2947	REF9, REF1, REF4, REF11	Yes
141	2022 2050 2092 2872	REF1, REF4, REF11, REF9	Yes
142	2385 2529 2794 2837	REF9, REF4, REF11, REF1	Yes
145	2027 2235 2287 2444 2514 2592 2680 2699 2904 2961 2967	REF5, REF9, REF1, REF3, REF11, REF4 REF7, REF2, REF8, REF6, REF 10	No

Writing error 2362

Annex 6. Reported band differences

Isolate no.	ST	Expected <i>Apal</i> bands	Laboratory ID						
			19	100	105	138	141	142	145
REF1 [†]	6	16	16	16	16	14	16	16	13
REF2	1	Clearly unrelated profile	15	15	15	15	15	14	13
REF3	6	18	18	18	18	16	18	18	16
REF4 [#]	6	16	16	16	16	14	16	16	13
REF5	6	16	16	16	16	14	16	16	14
REF6	6	16	16	16	16	15	16	16	15
REF7	213	Clearly unrelated profile	16	17	16	16	16	16	15
REF8	6	17	17	17	17	15	17	17	14
REF9 [#]	6	16	16	16	16	14	16	16	13
REF10	382	Clearly unrelated profile	16	16	16	16	16	15	14
REF11 [†]	6	16	16	16	16	14	16	16	11

Isolate no.	ST	Shared <i>Apal</i> bands	Laboratory ID						
			19	100	105	138	141	142	145
REF1 [†]	6	16	16	16	16	14	16	16	3
REF2	1	Clearly unrelated profile	9	6	13	9999	9999	10	0
REF3	6	15	15	14	15	9999	9999	15	4
REF4 [#]	6	16	16	16	16	14	16	16	4
REF5	6	15	15	15	15	9999	15	15	3
REF6	6	15	15	15	15	15	15	15	2
REF7	213	Clearly unrelated profile	5	5	10	9999	9999	8	5
REF8	6	16	16	16	16	15	16	15	3
REF9 [#]	6	16	16	16	16	14	16	16	3
REF10	382	Clearly unrelated profile	8	5	11	9999	9999	8	3
REF11 [†]	6	16	16	16	16	14	16	16	2

Isolate no.	ST	Expected <i>AscI</i> bands	Laboratory ID						
			19	100	105	138	141	142	145
REF1 [†]	6	8	8	8	8	8	8	8	8
REF2	1	Clearly unrelated profile	10	10	9	8	10	10	9
REF3	6	8	8	8	8	8	8	8	8
REF4 [#]	6	8	8	8	8	8	8	8	8
REF5	6	8	8	8	8	8	8	8	8
REF6	6	8	8	8	8	8	8	8	8
REF7	213	Clearly unrelated profile	10	11	11	10	11	11	10
REF8	6	8	8	8	8	8	8	8	8
REF9 [#]	6	8	8	8	8	8	8	8	8
REF10	382	Clearly unrelated profile	11	11	12	11	11	11	11
REF11 [†]	6	8	8	8	8	8	8	8	8

Isolate no.	ST	Shared <i>AscI</i> bands	Laboratory ID						
			19	100	105	138	141	142	145
REF1 [†]	6	8	8	8	8	8	8	8	3
REF2	1	Clearly unrelated profile	3	3	4	9999	9999	4	0
REF3	6	7	7	7	7	8	7	7	3
REF4 [#]	6	8	8	8	8	8	8	8	0
REF5	6	7	7	7	7	8	7	7	0
REF6	6	8	8	8	8	8	8	8	0
REF7	213	Clearly unrelated profile	4	5	6	9999	9999	5	2
REF8	6	7	7	6	7	8	7	7	0
REF9 [#]	6	8	8	8	8	8	8	8	0
REF10	382	Clearly unrelated profile	3	4	5	9999	9999	4	1
REF11 [†]	6	8	8	8	8	8	8	8	0

[†]Cluster identification of closely related isolates (based on PFGE-derived data)

[#]Technical duplicate

ST: Sequence type

9999: Not reported by laboratory.

Annex 7. Reported sequencing details

Sequencing performed	Protocol (library prep)	Commercial kit	Sequencing platform
In own laboratory	Commercial kits	Nextera XT DNA library Preparation Kit*	HiSeq2500
In own laboratory	Commercial kits	NEBNext® Fast DNA Fragmentation & Library Prep Set for Ion Torrent, New England 'Biolabs**	Ion Torrent PGM
Externally	Commercial kits	Illumina	HiSeq 2500
In own laboratory	Commercial kits	Ion Xpress™ Plus Fragment Library Kit for AB Library Builder™ System	IonTorrent S5XL
In own laboratory	Commercial kits	Nextera XT	MiSeq
In own laboratory	Commercial kits	NEXTERA	MiSeq
In own laboratory	Commercial kits	SureSelect QXT Library Prep Kit (Agilent)	MiSeq
In own laboratory	Commercial kits	Nextera XT DNA Library Preparation Kit	MiSeq
In own laboratory	Commercial kits	Nextera XT	MiSeq
In own laboratory	Commercial kits	Nextera XT***	Miniseq
In own laboratory	Commercial kits	Nextera XT Libray Prep kit (96 samples)***	NextSeq
In own laboratory	Commercial kits	Illumina Nextera XT library Prep Kit	MiSeq

* 5ng input DNA (as opposed to 1ng)

Altered PCR protocol to favour longer fragment sizes

Adjustment of extension temperature (and final extension) from 72° to 65°C

'Manual' normalisation using library concentration and fragment size as opposed to bead-based normalisation.

** Shearing carried out for 15 minutes at 25°C instead of 20 minutes because 400bp sequencing protocol was used

*** Half volume for all reagents.

Annex 8. Reported cluster of closely related isolates based on WGS-derived data

Lab ID	Reported cluster	Corresponding to REF isolates	Correct
Provider	REF1, REF4, REF9, REF11 (4 and 9 technical duplicates)		
19	#3562 3539 2691 2719	REF4, REF1 REF9, REF11	Yes
35	2251 2737 2783 2993	REF11, REF9, REF1, REF4	Yes
56	2341 2165 2612	REF9, REF1, REF11	Yes
70	2104 2216 2567 2767	REF4, REF1, REF11, REF9	Yes
105	2073 2805 2978	REF4, REF1, REF11	Yes
108	2098 2788 2582 2422	REF1, REF11, REF9, REF4	Yes
129	2079 2640 2912 2950	REF1, REF9, REF11, REF4	Yes
135	2161 2423 2673 2897	REF1, REF4, REF11, REF9	Yes
141	2022 2050 2092 2872	REF1, REF4, REF11, REF9	Yes
142	2385 2529 2794 2837	REF9, REF4, REF11, REF1	Yes
144	2143 2626 2727 2822	REF4, REF11, REF1, REF9	Yes
146	2068 2197 2377 2488 ##2353 2575 2655 2726	REF5, REF8, REF3, REF1, REF6, REF4, REF9, REF11	No

#Writing error 2362

##Writing error 2553

Annex 9. Reported SNP distance and allelic differences

SNP distances

Isolate no.	ST	Provider	Laboratory ID					
			19*	56	105	108	142*	146
REF1 [†]	6	3	4	0 [‡]	1	2	1030	306
REF2	1	9999	9999	9999	812	9999	7502	9999
REF3	6	41	47	579	23	45	2814	0 [‡]
REF4 ^{‡#}	6	0 [‡]	0 [‡]	9999	1	2	1219	309
REF5	6	40	43	561	24	37	2056	259
REF6	6	72	81	591	42	72	2732	358
REF7	213	9999	9999	9999	734	9999	8050	9999
REF8	6	39	43	9999	22	40	1223	48
REF9 ^{‡#}	6	0	0	57	9999	2	0 [‡]	296
REF10	382	9999	9999	6109	745	9999	8138	9999
REF11 [†]	6	1	2	48	0 [‡]	0 [‡]	1114	304

Allelic distances

Isolates no.	ST	Provider	Laboratory ID								
			19	35	70	105*	129	135	141	142	144
REF1 [†]	6	3	3	1	1	1	4	1	7	0	1
REF2	1	1118	1120	1065	1062	812	862	2042	1060	1120	1065
REF3	6	25	25	16	16	23	15	16	19	16	16
REF4 ^{‡#}	6	0 [‡]	0 [‡]	2	2	1	0	2	0 [‡]	0	2
REF5	6	26	26	18	18	24	17	17	20	13	18
REF6	6	44	43	35	35	42	32	50	38	41	36
REF7	213	1073	1070	1028	1026	734	842	1031	1024	1074	1028
REF8	6	28	28	24	24	22	20	39	26	22	24
REF9 ^{‡#}	6	0	0	2	2	9999	0 [‡]	2	0	0 [‡]	2
REF10	382	1060	1060	1027	1021	745	839	1592	1025	1063	1027
REF11 [†]	6	3	2	0 [‡]	0 [‡]	0 [‡]	2	0 [‡]	2	0	0 [‡]

* Additional analysis

‡ Closely related isolates

Technical duplicate isolate

‡ Isolate used as cluster representative by participant

9999: Isolates not included in analysis by participant

ST: Sequence type

Annex 10. Reported QC parameters

QC parameters	Thresholds
Coverage	50
Coverage	20 x
Average coverage	>29
Coverage	>40
Coverage after trimming	>50x
Coverage	60x
Average coverage	>35-fold
Coverage	>50
Minimum per site coverage of assembly	25
Difference of sum of contig length with average coverage >0 and >25	250000
Difference of number of contigs with average coverage >0 and >25	1000
Depth of coverage	>45X
Percentage of good targets	0,9
Percentage of cgMLST loci found	>97%
Good target for cgMLST	>= 98%
Number of good cgMLST targets	Minimum 90 %
Percentage of good targets	>99%
cgMLST alleles found and called	>95%
cgMLST genes present	>=95%
Genome size	+/- 20%
Assembly length	<4 Mb
Consensus base count assembled	Approximate size of genome (for <i>Listeria</i> ~ 2.8 million)
Length of contig assembly	< reference genome + 10%
Assembly length	>2.8Mb and <3.1Mb
Total length	<=3Mb
Confirmation of genus/species	Only <i>L. monocytogenes</i> culture Main genus match in kraken must match supplied genus Only one genus >5% on mini kraken
Mixed culture check	
Confirmation of genus (JSpecies)	
Confirmation of genus	
Contamination check	
Specie confirmation by KAMERS	
Specie confirmation by KAMERS	
Kmer Identification	
Number of contigs	200 bases
Number of contigs	<1000
Number of contigs	<100
Q score (Phred)	20
Phred score	>28
Per sequence quality score before trimming	Passed using FastQC
Fast QC: per sequence quality score	
Q30	70-80%
Per sequence quality score	Q>30
Per sequence GC content before trimming	Passed using FastQC
Fast QC: per base sequence content	
Per base sequence quality before trimming	Passed using FastQC
Fast QC: per base sequence quality	
N50	200000
N50	
Alignment with 7 housekeeping genes of MLST panel	No mismatches
Overrepresented sequence before trimming	Passed using FastQC
Fast QC: per sequence length distribution	
Target QC procedure	Length of consensus equals ref.-seq. area(s) length +/- 3 triplets
PHiX control (internal control for run performance)	
cluster density	~1200-1400 K/mm3
Percentage mapping with reference genome	>90%
identity to reference sequence	>=90%
Alignment to reference sequence	0,01
Metric post-trim yield	>90Mb
FASTQC metrics	Default metrics
Unexplained similarity differences only reported if > 10%	

Annex 11. Calculated qualitative/quantitative parameters

		Laboratory 19										
Quali-/Quantitative	Ranges*	2374	2067	2605	2648	2025	2539	2669	2719	2691	2362	2756
Number of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1
Detected species	{ <i>Lm</i> }	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		1.58	1.81	2.46	1.61	1.47	1.65	1.76	1.84	2.07	1.64	1.52
Length at 25 x min. coverage (Mbp)	{>2.8 ∧ <3.1}	2.9	2.9	3.0	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	16	19	21	16	15	14	20	16	15	17	18
Number of contigs [0-25] x min. coverage	{<1000}	0	0	0	0	0	0	0	0	0	0	0
Average coverage	{>50}	160.3	193.8	171.7	207.6	160.7	209.0	195.7	207.7	173.1	223.6	204.3
Number of reads (x 1000)		1741.0	2134	1935	2280	1738	2286	2152	2288	1900	2457	2220
Number of trimmed reads (x1000)		1721.4	2108	1912	2252	1718	2258	2127	2259	1877	2428	2193
Maximum read length		151	151	151	151	151	151	151	151	151	151	151
Mean read length		141.6	142.1	139.6	141.3	142.1	141.9	140.5	140.9	140.1	141.5	140.9
Read insert size		290.7	280.0	266.9	268.8	304.9	287.7	268.6	275.0	281.9	279.8	267.0
Insert size StdDev		105.1	100.9	100.9	100.3	105.1	105.7	103.8	101.3	104.1	103.9	101.5
N50 (kbp)		285.3	353.1	406.5	551.2	551.1	515.1	237.6	510.1	510.2	510.1	514.8
N75 (kbp)		237.6	143.0	190.5	237.7	257.3	257.3	184.4	237.6	257.3	237.7	237.6

		Laboratory 35										
Quali-/Quantitative	Ranges*	2737	2055	2251	2008	2874	2783	2983	2162	2993	2689	2355
Number of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1
Detected species	{ <i>Lm</i> }	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		1.92	1.75	0.72	2.13	0.74	2.53	1.06	0.58	0.62	0.55	2.18
Length at 25 x min. coverage (Mbp)	{>2.8 ∧ <3.1}	2.9	3.0	2.9	2.9	2.9	2.9	3.0	2.9	2.9	2.9	2.9
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	16	25	14	15	16	14	12	19	20	13	13
Number of contigs [0-25] x min. coverage	{<1000}	0	0	0	0	0	0	0	0	0	0	0
Average coverage	{>50}	40.4	60.6	67.3	79.8	49.2	77.7	73.1	126.6	111.1	166.0	175.1
Number of reads (x 1000)		250.3	370.2	406.0	534.3	301.9	535.7	439.3	744.1	656.3	993.8	1120.3
Number of trimmed reads (x1000)		247.9	368.6	402.0	530.5	299.9	533.4	437.6	740.9	652.8	987.7	1110.1
Maximum read length		301	301	301	301	301	301	301	301	301	301	301
Mean read length		239.1	246.3	246.4	221.8	240.8	214.5	248.5	249.2	251.2	249.0	233.3
Read insert size		394.1	376.1	347.0	341.6	351.5	332.8	369.0	364.3	367.1	367.3	370.7
Insert size StdDev		199.1	181.8	158.4	176.6	174.4	173.9	183.0	176.0	176.7	182.5	186.5
N50 (kbp)		510.4	274.4	515.4	551.6	320.7	510.4	356.3	504.2	299.2	556.4	558.1
N75 (kbp)		257.4	138.4	262.2	258.0	262.8	257.4	227.3	257.4	255.6	257.4	257.7

		Laboratory 56						
Quali-/Quantitative	Ranges*	2165	2636	2178	2612	2341	2811	2813
Number of genera detected	{1}	1	1	1	1	1	1	1
Detected species	{ <i>Lm</i> }	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		0.89	1.32	0.72	1.0	0.79	2.23	0.58
Length at 25 x min. coverage (Mbp)	{>2.8 \wedge <3.1}	1.8	2.7	2.0	1.9	2.2	1.9	2.1
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	1009	876	1054	1005	1056	1006	1008
Number of contigs [0-25] x min. coverage	{<1000}	0	0	0	0	0	0	0
Average coverage	{>50}	60.5	84.2	76.4	77.0	92.6	103.8	85.0
Number of reads (x 1000)		707.0	832.7	889.4	938.4	1045.2	1277.9	956.1
Number of trimmed reads (x1000)		690.9	813.1	871.1	915.1	1023.3	1235.1	936.7
Maximum read length		325	285	325	365	295	340	325
Mean read length		224.8	223.6	224.7	217.4	227.6	228.8	226.7
Read insert size		NA	NA	NA	NA	NA	NA	NA
Insert size StdDev		NA	NA	NA	NA	NA	NA	NA
N50 (kbp)		1.4	3.4	1.6	1.5	1.8	1.5	1.8
N75 (kbp)		0.9	1.9	1.0	0.9	1.1	0.9	1.1

		Laboratory 70										
Quali-/Quantitative	Ranges*	2104	2216	2300	2219	2397	2567	2606	2767	2424	2695	2903
Number of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1
Detected species	{ <i>Lm</i> }	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		1.49	2.54	2.17	1.78	1.99	2.18	2.86	2.38	1.96	1.87	1.96
Length at 25 x min. coverage (Mbp)	{>2.8 \wedge <3.1}	2.9	2.9	2.9	2.9	2.9	2.9	3.0	2.9	2.9	2.9	2.9
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	22	25	24	17	26	22	45	21	19	38	23
Number of contigs [0-25] x min. coverage	{<1000}	1	0	0	0	0	0	1	1	0	4	0
Average coverage	{>50}	81.3	57.6	50.7	99.8	66.4	67.3	60.0	60.2	64.6	60.4	83.1
Number of reads (x 1000)		830.4	600.8	527.9	1034.9	678.0	694.0	636.7	626.4	672.2	625.3	857.7
Number of trimmed reads (x1000)		826.1	595.9	524.2	1028.0	673.2	687.9	631.5	621.2	668.2	622.3	850.7
Maximum read length		151	151	151	151	151	151	151	151	151	151	151
Mean read length		145.5	142.7	142.6	144.5	143.8	144.5	142.6	143.2	143.1	144.5	144.7
Read insert size		391.0	335.3	327.0	312.8	325.4	329.0	313.7	324.7	288.1	383.6	314.0
Insert size StdDev		147.0	124.8	126.4	111.1	115.8	112.1	115.9	116.8	100.3	148.9	107.0
N50 (kbp)		238.2	238.0	234.6	317.7	223.0	239.1	143.1	295.1	238.0	162.3	261.4
N75 (kbp)		139.4	186.2	168.3	238.2	164.2	218.6	92.5	164.8	184.4	78.2	185.7

		Laboratory 105										
Quali-/Quantitative	Ranges*	2073	2281	2709	2327	2677	2701	2450	2391	2978	2782	2805
Number of genera detected	{1}	1	1	2	1	1	1	1	1	1	1	1
Detected species	{ <i>Lm</i> }	Lm	Lm	N	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		1.79	0.89	50.81	1.65	1.51	0.36	0.98	0.78	1.17	1.57	0.57
Length at 25 x min. coverage (Mbp)	{>2.8 \wedge <3.1}	2.9	2.9	0.1	3.0	2.9	2.9	2.9	2.9	2.9	3.0	3.0
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	29	20	21	18	22	116	20	15	17	14	193
Number of contigs [0-25] x min. coverage	{<1000}	0	0	517	0	0	0	0	0	0	0	0
Average coverage	{>50}	76.9	83.9	17.5	77.2	81.1	93.2	81.9	83.8	76.9	83.9	93.8
Number of reads (x 1000)		578.1	577.8	344.6	551.2	592.4	611.3	567.9	574.2	533.6	589.6	622.1
Number of trimmed reads (x1000)		569.1	567.6	341.9	538.6	582.3	592.6	554.6	558.3	527.2	578.6	609.1
Maximum read length		301	301	301	301	301	301	301	301	301	301	301
Mean read length		204.0	220.1	121.0	216.9	208.7	239.0	217.0	222.9	216.3	218.4	240.5
Read insert size		298.0	320.3	199.2	320.9	308.1	358.9	319.1	331.6	315.7	322.6	363.3
Insert size StdDev		142.7	153.1	67.3	155.7	149.7	150.7	152.9	155.9	152.3	155.2	157.7
N50 (kbp)		206.1	299.8	1.3	406.6	295.8	54.8	255.6	295.2	302.6	353.2	26.6
N75 (kbp)		105.2	225.1	0.8	183.0	257.4	26.4	200.9	257.4	262.0	201.1	13.4

		Laboratory 108										
Quali-/Quantitative	Ranges*	2086	2118	2297	2098	2422	2844	2582	2446	2716	2562	2788
Number of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1
Detected species	{ <i>Lm</i> }	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		1.72	1.18	1.25	1.26	1.35	1.07	1.39	1.84	1.42	1.09	1.21
Length at 25 x min. coverage (Mbp)	{>2.8 ∧ <3.1}	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	2.9	2.9	2.9
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	103	105	74	121	57	113	99	146	64	136	119
Number of contigs [0-25] x min. coverage	{<1000}	0	0	1	0	0	0	0	0	5	0	0
Average coverage	{>50}	41.0	48.9	31.1	67.2	30.7	63.6	46.9	70.1	30.0	60.4	60.8
Number of reads (x 1000)		397.1	467.1	285.2	643.3	285.8	607.2	455.4	688.8	284.7	586.0	583.5
Number of trimmed reads (x1000)		354.7	420.6	258.7	593.1	253.8	532.4	404.9	616.9	263.0	521.0	522.5
Maximum read length		318	319	317	258	319	314	315	313	241	314	318
Mean read length		192.6	193.9	194.5	194.6	193.8	199.9	192.3	199.3	185.7	197.2	196.7
Read insert size		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Insert size StdDev		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
N50 (kbp)		52.0	51.3	60.9	50.8	74.0	44.3	50.1	37.0	87.0	34.0	40.9
N75 (kbp)		28.3	30.4	38.8	22.5	41.7	26.4	27.0	22.5	45.4	22.5	25.6

		Laboratory 129										
Quali-/Quantitative	Ranges*	2079	2320	2518	2646	2204	2635	2950	2640	2979	2951	2912
Number of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1
Detected species	{ <i>Lm</i> }	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		1.16	1.53	0.9	1.32	0.63	1.0	0.99	1.29	1.48	1.06	1.7
Length at 25 x min. coverage (Mbp)	{>2.8 ∧ <3.1}	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	32	47	22	19	16	15	16	16	16	17	17
Number of contigs [0-25] x min. coverage	{<1000}	24	11	1	0	0	0	0	0	0	0	0
Average coverage	{>50}	67.1	50.0	78.3	129.8	126.3	149.6	167.6	94.9	116.7	134.5	244.4
Number of reads (x 1000)		704.5	530.4	810.2	1388	1323	1583	1774	1010	1267	1421	2704
Number of trimmed reads (x1000)		698.7	523.2	798.9	1367	1301	1558	1758	997	1256	1397	2677
Maximum read length		151	151	151	151	151	151	151	151	151	151	151
Mean read length		145.4	143.4	144.9	143.3	144.7	142.1	143.6	141.9	139.2	143.4	140.0
Read insert size		350.9	449.8	427.5	336.5	325.5	273.7	276.2	271.5	256.1	359.1	243.9
Insert size StdDev		139.5	196.0	170.8	134.9	125.4	115.1	119.8	125.3	134.3	144.3	107.5
N50 (kbp)		254.9	124.8	282.9	353.1	510.2	510.3	510.0	510.0	551.2	367.6	510.2
N75 (kbp)		78.5	60.9	209.4	198.2	255.0	257.9	254.9	254.9	254.9	195.1	254.9

		Laboratory 135										
Quali-/Quantitative	Ranges*	2056	2115	2465	2284	2161	2273	2585	2423	2715	2673	2897
Number of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1
Detected species	{ <i>Lm</i> }	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		1.01	0.47	0.88	0.51	0.72	0.63	0.64	0.8	0.47	0.68	0.78
Length at 25 x min. coverage (Mbp)	{>2.8 ∧ <3.1}	3.0	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	24	19	23	18	19	18	17	19	19	19	17
Number of contigs [0-25] x min. coverage	{<1000}	0	0	0	0	0	0	0	0	0	0	0
Average coverage	{>50}	199.3	207.6	187.7	153.2	193.7	198.6	198.2	219.0	221.0	175.1	197.3
Number of reads (x 1000)		2578.9	2647	2396	1898	2454	2518	2519	2808	2835	2214	2504
Number of trimmed reads (x1000)		2547.9	2612	2366	1878	2426	2488	2486	2775	2800	2189	2479
Maximum read length		126	126	126	126	126	126	126	126	126	126	126
Mean read length		123.8	123.6	123.7	123.3	123.3	123.4	123.3	122.8	123.7	123.3	123.1
Read insert size		348.1	341.1	351.4	345.5	337.4	335.7	338.8	338.4	342.3	343.7	326.3
Insert size StdDev		178.2	178.3	178.1	184.1	175.0	173.5	179.1	188.3	177.7	184.4	173.7
N50 (kbp)		406.7	481.8	353.1	440.5	440.7	294.8	481.8	440.8	440.8	440.7	440.8
N75 (kbp)		142.1	257.3	142.9	237.9	237.9	254.7	257.9	237.9	237.9	237.9	254.8

		Laboratory 141										
Quali-/Quantitative	Ranges*	2022	2535	2092	2050	2207	2509	2510	2872	2177	2194	2464
Number of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1
Detected species	{Lm}	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		1.81	1.47	1.0	1.37	0.98	0.91	1.67	1.39	1.77	1.4	1.71
Length at 25 x min. coverage (Mbp)	{>2.8 ∧ <3.1}	1.0	3.0	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	2.9
Length [0-25] x min. coverage (Mbp)	{<0.25}	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	57	41	31	85	35	35	29	70	43	37	19
Number of contigs [0-25] x min. coverage	{<1000}	165	1	0	0	0	0	0	7	1	1	0
Average coverage	{>50}	24.3	57.7	69.5	80.2	77.3	66.4	63.3	46.9	85.1	91.9	126.1
Number of reads (x 1000)		157.6	385.6	479.8	560.8	508.9	450.9	423.5	327.0	574.2	622.1	882.9
Number of trimmed reads (x1000)		150.2	374.1	461.0	547.0	492.0	434.8	412.8	311.4	552.5	604.6	864.8
Maximum read length		301	301	301	301	301	301	301	301	301	301	301
Mean read length		235.3	233.0	222.9	220.0	232.5	226.0	226.5	221.7	225.2	228.3	217.5
Read insert size		358.3	310.2	286.4	278.8	308.3	296.0	313.0	296.5	316.9	295.7	278.9
Insert size StdDev		130.0	117.4	103.9	104.1	111.7	110.8	115.9	103.8	116.6	109.2	102.0
N50 (kbp)		22.4	186.5	165.2	72.8	160.0	197.3	255.6	69.3	122.1	140.3	262.9
N75 (kbp)		11.4	96.8	98.0	35.1	95.3	91.8	98.7	43.1	84.9	99.8	235.6

		Laboratory 142										
Quali-/Quantitative	Ranges*	2040	2330	2077	2385	2441	2408	2529	2977	2837	2670	2794
Number of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1
Detected species	{Lm}	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		1.03	0.93	1.04	1.2	0.87	1.39	1.23	0.81	0.97	1.2	1.0
Length at 25 x min. coverage (Mbp)	{>2.8 ∧ <3.1}	2.9	2.9	2.9	2.9	2.9	3.0	2.9	2.9	2.9	3.0	2.9
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	17	13	15	15	13	15	14	15	15	17	13
Number of contigs [0-25] x min. coverage	{<1000}	2	0	0	1	0	0	0	0	0	0	0
Average coverage	{>50}	46.5	53.9	57.4	44.6	40.2	53.8	56.6	54.1	48.1	58.1	54.6
Number of reads (x 1000)		313.7	359.6	384.8	299.2	260.6	357.5	375.8	351.1	318.6	384.2	358.3
Number of trimmed reads (x1000)		307.5	353.2	379.9	295.4	256.6	351.5	367.2	345.3	312.6	376.0	350.5
Maximum read length		251	251	251	251	251	251	251	251	251	251	251
Mean read length		224.7	227.3	225.4	225.4	233.2	230.9	231.0	230.5	229.2	233.9	232.6
Read insert size		367.1	378.4	362.9	361.1	393.5	385.4	389.5	377.7	379.0	399.0	392.6
Insert size StdDev		171.4	174.3	167.4	152.3	162.9	162.5	164.6	160.8	157.2	160.8	165.0
N50 (kbp)		261.7	556.2	510.2	515.2	551.4	353.2	413.6	320.8	324.3	306.7	515.2
N75 (kbp)		225.0	257.4	257.4	262.0	255.6	198.3	257.4	257.4	262.0	238.2	262.0

		Laboratory 144										
Quali-/Quantitative	Ranges*	2143	2112	2490	2470	2626	2727	2814	2818	2964	2822	2892
Number of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1
Detected species	{Lm}	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		0.38	0.29	0.28	1.31	0.43	0.42	0.35	0.81	0.31	0.34	0.24
Length at 25 x min. coverage (Mbp)	{>2.8 ∧ <3.1}	2.9	2.9	2.9	3.0	2.9	2.9	2.9	2.9	2.9	2.9	2.9
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	13	13	12	17	13	13	14	14	11	14	12
Number of contigs [0-25] x min. coverage	{<1000}	0	0	0	0	0	0	0	0	0	0	0
Average coverage	{>50}	110.0	78.4	87.4	76.3	86.4	85.5	106.5	75.4	97.4	127.8	112.3
Number of reads (x 1000)		766.0	546.5	596.3	590.8	609.2	588.9	724.0	525.9	685.1	881.3	774.2
Number of trimmed reads (x1000)		749.8	534.2	588.8	558.5	592.4	582.6	716.1	518.1	672.3	870.3	763.7
Maximum read length		251	251	251	251	251	251	251	251	251	251	251
Mean read length		224.1	218.8	225.6	210.3	220.8	223.1	227.3	222.7	220.9	226.2	225.7
Read insert size		320.4	296.4	315.9	279.6	306.2	307.9	326.7	309.6	303.6	317.6	322.0
Insert size StdDev		118.5	104.6	113.1	92.6	109.5	114.9	124.7	116.8	113.5	116.9	121.5
N50 (kbp)		515.4	510.1	515.0	406.6	510.1	515.2	558.1	353.2	556.2	510.3	556.2
N75 (kbp)		262.0	257.4	262.9	183.0	262.0	262.0	257.7	200.7	258.0	262.1	257.4

		Laboratory 146										
Quali-/Quantitative	Ranges*	2160	2068	2726	2197	2463	2536	2377	2575	2553	2488	2655
Number of genera detected	{1}	1	1	1	1	1	1	1	1	1	1	1
Detected species	{ <i>Lm</i> }	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm	Lm
Unclassified reads (%)		0.73	0.55	1.12	0.52	1.27	0.69	0.79	0.41	0.53	1.25	1.97
Length at 25 x min. coverage (Mbp)	{>2.8 ∧ <3.1}	2.9	2.9	3.0	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
Length [0-25] x min. coverage (Mbp)	{<0.25}	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Number of contigs at 25 x min. coverage	{>0}	21	17	25	19	20	20	21	20	17	20	23
Number of contigs [0-25] x min. coverage	{<1000}	0	0	0	0	0	0	0	0	1	0	0
Average coverage	{>50}	181.9	194.8	160.1	174.9	145.9	179.4	149.5	140.4	151.6	199.7	187.0
Number of reads (x 1000)		2786.9	3024	2537	2746	2346	2807	2330	2148	2301	3169	3066
Number of trimmed reads (x1000)		2786.8	3024	2537	2746	2346	2807	2330	2148	2300	3169	3066
Maximum read length		101	101	101	101	101	101	101	101	101	101	101
Mean read length		99.4	99.5	99.0	99.5	96.6	99.4	99.2	99.6	99.4	98.5	96.8
Read insert size		307.7	310.4	290.7	310.2	207.8	324.9	266.1	359.6	323.2	225.0	204.0
Insert size StdDev		160.2	138.9	158.0	139.5	81.1	167.9	120.7	162.7	168.8	108.4	85.2
N50 (kbp)		285.9	440.8	406.4	481.8	425.0	440.8	440.8	440.5	440.8	509.9	353.1
N75 (kbp)		154.7	261.8	200.4	257.3	254.8	257.3	237.9	257.3	255.0	257.9	144.2

Quality assessment made by the EQA-provider in-house quality control pipeline.

* Indicative QC ranges

Lm: *L. monocytogenes*

N: *Neisseria*.

Annex 12. EQA-5 laboratory questionnaire

This is a preview of all the fields and questions available.

Please keep in mind that, depending on your answers in the questionnaire, you will not necessarily have to answer all the questions.

1. Listeria EQA-5 2017

Dear Participant,

Welcome to the fifth External Quality Assessment (EQA-5) scheme for typing of *Listeria* in 2017–2018. Please note that most of the fields are required to be filled in before the submission can be completed. Any comments can be written at the end of the form. You are always welcome to contact us at list.eqa@ssi.dk.

Please start by filling in your country, your Laboratory name and your LAB_ID.

Available options in this submission form include:

- Click 'Options' and 'Pause' to save your results and finish at a later time (using the same link)
- Click 'Options' and 'Print' to print your answers. This can be done at any time, but before pressing 'Submit results'
- Click 'Previous' to go back to the questions you have already answered
- Click 'Options' and 'Go to' to go back to a specific page number

Note: After pressing 'Submit results' you will not be able to review your results.

2. Country

- ☐ Austria
- ☐ Belgium
- ☐ Czech Republic
- ☐ Denmark
- ☐ Estonia
- ☐ Finland
- ☐ France
- ☐ Germany
- ☐ Greece
- ☐ Hungary
- ☐ Ireland
- ☐ Italy
- ☐ Latvia
- ☐ Lithuania
- ☐ Luxembourg
- ☐ Malta
- ☐ Norway
- ☐ Portugal
- ☐ Romania
- ☐ Scotland
- ☐ Serbia
- ☐ Slovak Republic
- ☐ Slovenia
- ☐ Spain
- ☐ Sweden
- ☐ Netherlands
- ☐ Turkey
- ☐ UK

3. Laboratory name

4. Laboratory ID

Consisting of country code (two letters) Lab ID on the vial e.g. DK_SSI

5. E-mail

6. Serotyping of *Listeria*

7. Submitting results

- ☐ Online here (please fill in the strain IDs in the following section)
☐ Did not participate in the serotyping part

8. Serotyping strain IDs

Please enter the strain ID (4 digits)

Listeria

Strain 1 ____
 Strain 2 ____
 Strain 3 ____
 Strain 4 ____
 Strain 5 ____
 Strain 6 ____
 Strain 7 ____
 Strain 8 ____
 Strain 9 ____
 Strain 10 ____
 Strain 11 ____

9. Submitting results – serotyping of *Listeria*

- ☐ Both molecular and conventional serotyping
☐ Molecular serotyping
☐ Conventional serotyping

10. Results for serotyping *Listeria* – molecular serotyping

Please select the serotype

Strain	Serotype					
	IIa	IIb	IIc	IVb	L	Untypeable
Strain 1						
Strain 2						
Strain 3						
Strain 4						
Strain 5						
Strain 6						
Strain 7						
Strain 8						
Strain 9						
Strain 10						
Strain 11						

11. Submitting results – conventional serotyping *Listeria*

- ☐ Online here (please fill in the results for conventional serotyping in the following section)
☐ Did not participate in conventional serotyping part for *Listeria*

12. Results for serotyping *Listeria* – conventional serotyping. Please select the serotype

Strain	Serotype														
	1/2a	1/2b	1/2c	3a	3b	3c	4a	4ab	4b	4c	4d	4e	7	Autoagglutinable	Untypeable
Strain 1															
Strain 2															
Strain 3															
Strain 4															
Strain 5															
Strain 6															
Strain 7															
Strain 8															
Strain 9															
Strain 10															
Strain 11															

13. Submitting cluster results

- ☐ Cluster analyses based on PFGE and/or WGS
☐ Did not participate in the cluster part

14. Cluster strain IDs. Please enter the cluster strain ID (4 digits)

Cluster strain ID

Strain 1 _____
 Strain 2 _____
 Strain 3 _____
 Strain 4 _____
 Strain 5 _____
 Strain 6 _____
 Strain 7 _____
 Strain 8 _____
 Strain 9 _____
 Strain 10 _____
 Strain 11 _____

15. Submitting cluster results

- ☐ Cluster analysis based on PFGE
☐ Do not wish to submit any cluster results based on PFGE analysis

16. Cluster analysis based on PFGE data

17. Please list the ID for the strains included in the cluster detected by PFGE combining Apal and AscI results

Please use semicolon (;) to separate the IDs

18. Select a representative strain with the cluster profile detected by PFGE

Indicate the strain ID

19. Apal – Total number of bands (>33kb) in the selected representative cluster strain

20. AscI – Total number of bands (>33kb) in the selected representative cluster strain

21. Results for cluster analysis – PFGE (ApaI and AscI)

Please use '9999' for 'not analysed'

	ApaI – Total number of bands (>33kb)	ApaI – Number of bands with same/shared position as the profile of the selected cluster strain (>33kb)	AscI – Total number of bands (>33kb)	AscI – Number of bands with same/shared position as the profile of the selected cluster strain (>33kb)
Strain 1				
Strain 2				
Strain 3				
Strain 4				
Strain 5				
Strain 6				
Strain 7				
Strain 8				
Strain 9				
Strain 10				
Strain 11				

22. Submitting cluster results

- ☐ Cluster analysis based on WGS data
☐ Do not wish to submit any cluster results based on WGS data

23. Cluster analysis based on WGS data

24. Please select the analysis used to detect the cluster on data derived from WGS

As basis for the cluster detection only one data analysis can be reported. If more than one analysis is performed, please report later in this submission

- ☐ SNP-based
☐ Allele-based
☐ Other

25. If another analysis is used, please describe your approach

26. Please select the approach used for the SNP analysis

- ☐ Reference-based
☐ Assembly-based

27. Reference genome used

Please indicate multilocus sequence type (e.g. ST8) and strain ID (e.g. one of the strains from the current cluster, ID of a public reference strain or an in-house strain)

28. Please indicate the read mapper used (e.g. BWA, Bowtie2)

29. Please indicate the variant caller used, e.g. SAMtools, GATK

30. Please indicate the assembler used, e.g. SPAdes, Velvet

31. Please specify the variant caller used, e.g. NUCMER

32. Please select tools used for the allele analysis

- ☐ BioNumerics
- ☐ SeqSphere
- ☐ BIGSdb-Lm
- ☐ Other

33. If another tool is used, please enter here

34. Please indicate allele calling method

- ☐ Assembly-based and mapping-based
- ☐ Only assembly-based
- ☐ Only mapping-based

35. Please indicate the assembler used (e.g. SPAdes, Velvet)

36. Please select scheme used for the allele analysis

- ☐ Applied Math (wgMLST)
- ☐ Applied Math (cgMLST/Pasteur)
- ☐ Pasteur (cgMLST)
- ☐ Ruppitsch (cgMLST)
- ☐ Other

37. If another scheme (e.g. in-house) is used, please give a short description

38. Cluster detected by analysis on data derived from WGS

On this page you have to report the results for the cluster detected by the selected analysis (e.g. SNP based). If another additional analysis (e.g. allele based or another SNP based analysis) is performed, please report results later, but you will not be asked to submit the IDs for strains in the cluster detected with the additional analysis.

39. Please list the IDs for the strains included in the cluster

Please use semicolon (;) to separate the strain IDs

40. Select a representative strain in the cluster

Indicate the strain ID

41. Results for cluster analysis (e.g. SNP or allele-based)

Please use '9999' for 'not analysed'.

Distance (e.g. SNP) to the selected cluster strain

Strain 1	_____
Strain 2	_____
Strain 3	_____
Strain 4	_____
Strain 5	_____
Strain 6	_____
Strain 7	_____
Strain 8	_____
Strain 9	_____
Strain 10	_____
Strain 11	_____

42. Would you like to add results performed with another additional analysis on the data derived from the WGS?

If SNP based results are submitted, you can also report allele based results or results from a second SNP analysis

- ☐ Yes
☐ No

43. Please select the additional analysis used on data derived from WGS

- ☐ SNP-based
☐ Allele-based
☐ Other

44. If another analysis is used, please describe your approach:

45. Please select the approach used for the SNP analysis

- ☐ Reference-based
☐ Assembly-based

46. Reference genome used

Please indicate multi locus sequence type (e.g. ST8) and strain ID (e.g. one of the strains from the current cluster, ID of a public reference strain or an in-house strain)

47. Please indicate the read mapper used (e.g. BWA, Bowtie2)

48. Please indicate the variant caller used (e.g. SAMtools, GATK)

49. Please indicate the assembler used (e.g. SPAdes, Velvet)

50. Please specify the variant caller used (e.g. NUCMER)

51. Please select tool used for the allele analysis

- ☐ BioNumerics
- ☐ SeqPhere
- ☐ BIGSdb-Lm
- ☐ Other

52. If another tool is used, please list here:

53. Please indicate allele calling method

- ☐ Assembly-based and mapping-based
- ☐ Only assembly-based
- ☐ Only mapping-based

54. Please indicate the assembler used (e.g. SPAdes, Velvet)

55. Please select scheme used for the allele analysis

- ☐ Applied Math (wgMLST)
- ☐ Applied Math (cgMLST/Pasteur)
- ☐ Pasteur (cgMLST)
- ☐ Ruppitsch (cgMLST)
- ☐ Other

56. If another scheme (e.g. in-house) is used, please give a short description

57. Additional analysis on data derived from WGS

58. Select a representative strain in the cluster detected by the additional analysis

Indicate the strain ID

59. Results for the additional cluster analysis (e.g. SNP or Allele based)

Please use '9999' for 'not analysed'

Distance (e.g. SNP) to the selected cluster strain

Strain 1	_____
Strain 2	_____
Strain 3	_____
Strain 4	_____
Strain 5	_____
Strain 6	_____
Strain 7	_____
Strain 8	_____
Strain 9	_____
Strain 10	_____
Strain 11	_____

60. Would you like to add results performed with a third analysis on the data derived from the WGS?

If SNP based results are submitted, you can also report allele-based results or results from a second SNP analysis

- ☐ Yes
- ☐ No

61. Please select the third analysis used on data derived from WGS

- ☐ SNP-based
- ☐ Allele-based
- ☐ Other

62. If another analysis is used, please describe your approach:

63. Please select the approach used for the SNP analysis

- ☐ Reference-based
- ☐ Assembly-based

64. Reference genome used

Please indicate multilocus sequence type (e.g. ST8) and strain ID (e.g. one of the strains from the current cluster, ID of a public reference strain or an in-house strain).

65. Please indicate the read mapper used (e.g. BWA, Bowtie2)

66. Please indicate the variant caller used (e.g. SAMtools, GATK)

67. Please indicate the assembler used (e.g. SPAdes, Velvet)

68. Please specify the variant caller used (e.g. NUCMER)

69. Please select tool used for the allele analysis

- ☐ BioNumerics
- ☐ SeqPhere
- ☐ BIGSdb-Lm
- ☐ Other

70. If another tool is used, please enter here:

71. Please indicate allele calling method

- ☐ Assembly-based and mapping-based
- ☐ Only assembly-based
- ☐ Only mapping-based

72. Please indicate the assembler used (e.g. SPAdes, Velvet)

73. Please select scheme used for the allele analysis

- ☐ Applied Math (wgMLST)
- ☐ Applied Math (cgMLST/Pasteur)
- ☐ Pasteur (cgMLST)
- ☐ Ruppitsch (cgMLST)
- ☐ Other

74. If another scheme (e.g. in-house) is used, please give a short description

75. Third analysis on data derived from WGS

76. Select a representative strain in the cluster detected by the third analysis

Indicate the strain ID

77. Results for the third cluster analysis (e.g. SNP or Allele based)

Please use '9999' for 'not analysed'

Distance (e.g. SNP) to the selected cluster strain

Strain 1	_____
Strain 2	_____
Strain 3	_____
Strain 4	_____
Strain 5	_____
Strain 6	_____
Strain 7	_____
Strain 8	_____
Strain 9	_____
Strain 10	_____
Strain 11	_____

78. Additional questions to the WGS part

79. Where was the sequencing performed?

- ☐ In own laboratory
- ☐ Externally

80. Protocol used to prepare the library for sequencing

- ☐ Commercial kits
- ☐ Non-commercial kits

81. Please indicate name of commercial kit

82. If relevant, please list deviation from commercial kit shortly in bullet points

83. For non-commercial kit, please indicate a short summary of the protocol

84. The sequencing platform used

- ☐ Ion Torrent PGM
- ☐ Ion Torrent Proton
- ☐ Genome Sequencer Junior System (454)
- ☐ Genome Sequencer FLX System (454)
- ☐ Genome Sequencer FLX+ System (454)
- ☐ PacBio RS
- ☐ PacBio RS II
- ☐ HiScanSQ
- ☐ HiSeq 1000
- ☐ HiSeq 1500
- ☐ HiSeq 2000
- ☐ HiSeq 2500
- ☐ HiSeq 4000
- ☐ Genome Analyzer Ix
- ☐ MiSeq
- ☐ MiSeq Dx
- ☐ MiSeq FGx
- ☐ ABI SOLiD
- ☐ NextSeq
- ☐ MinION (ONT)
- ☐ Other

85. If another platform is used, please list here

86. Quantitative criteria used to evaluate the quality of sequence data

Please list up to 10 different criteria (e.g. coverage, N50, number of contigs)

87. Quantitative criteria 1

88. Threshold used for quantitative criteria 1

89. Quantitative criteria 2

90. Threshold used for quantitative criteria 2

91. Quantitative criteria 3

92. Threshold used for quantitative criteria 3

93. Quantitative criteria 4

94. Threshold used for quantitative criteria 4

95. Quantitative criteria 5

96. Threshold used for quantitative criteria 5

97. Quantitative criteria 6

98. Threshold used for quantitative criteria 6

99. Quantitative criteria 7

100. Threshold used for quantitative criteria 7

101. Quantitative criteria 8

102. Threshold used for quantitative criteria 8

103. Quantitative criteria 9

104. Threshold used for quantitative criteria 9

105. Quantitative criteria 10

106. Threshold used for quantitative criteria 10

107. Qualitative criteria used to evaluate the quality of sequence data

Please list up to 10 different criteria (e.g. contamination, confirmation of genus)

108. Qualitative criteria 1

109. If relevant, threshold used for qualitative criteria 1

110. Qualitative criteria 2

111. If relevant, threshold used for qualitative criteria 2

112. Qualitative criteria 3

113. If relevant, threshold used for qualitative criteria 3

114. Qualitative criteria 4

115. If relevant, threshold used for qualitative criteria 4

116. Qualitative criteria 5

117. If relevant, threshold used for qualitative criteria 5

118. Qualitative criteria 6

119. If relevant, threshold used for qualitative criteria 6

120. Qualitative criteria 7

121. If relevant, threshold used for qualitative criteria 7

122. Qualitative criteria 8

123. If relevant, threshold used for qualitative criteria 8

124. Qualitative criteria 9

125. If relevant, threshold used for qualitative criteria 9

126. Qualitative criteria 10

127. If relevant, threshold used for qualitative criteria 10

128. Comment(s) (e.g. remarks to the submission, the data analyses or the laboratory methods)

129. Thank you for your participation

Thank you for filling out the Submission form for the *Listeria* EQA-5.

For questions, please contact list.eqa@ssi.dk or phone +45 3268 8341 +45 3268 8372.

We highly recommend that you save this submission form by printing it. You will find the print option after pressing the 'Options' button.

Important: After pressing 'Submit results' you will no longer be able to edit or print your information.

For final submission, remember to press 'Submit results' after printing.

**European Centre for Disease
Prevention and Control (ECDC)**

Address:
Gustav III:s boulevard 40, SE-169 73 Solna,
Sweden

Tel. +46 858601000
Fax +46 858601001
www.ecdc.europa.eu

An agency of the European Union
www.europa.eu

Subscribe to our publications
www.ecdc.europa.eu/en/publications

Contact us
publications@ecdc.europa.eu

Follow us on Twitter
[@ECDC_EU](https://twitter.com/ECDC_EU)

Like our Facebook page
www.facebook.com/ECDC.EU

ECDC is committed to ensuring the transparency and independence of its work

In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. Declarations of interest must be received from any prospective contractor(s) before any contract can be awarded.
www.ecdc.europa.eu/en/aboutus/transparency

HOW TO OBTAIN EU PUBLICATIONS

Free publications:

- one copy:
via EU Bookshop (<http://bookshop.europa.eu>);
- more than one copy or posters/maps:
from the European Union's representations (http://ec.europa.eu/represent_en.htm);
from the delegations in non-EU countries (http://eeas.europa.eu/delegations/index_en.htm);
by contacting the Europe Direct service (http://europa.eu/europedirect/index_en.htm) or
calling 00 800 6 7 8 9 10 11 (freephone number from anywhere in the EU) (*).

(*) The information given is free, as are most calls (though some operators, phone boxes or hotels may charge you).

Priced publications:

- via EU Bookshop (<http://bookshop.europa.eu>).



Publications Office